A Goldhirsch List of publications - Oncology · PDF fileSchweiz med Wschr 109: 1741-42, 1979 9. ... 1983 28. Goldhirsch A, ... Prognostic significance of tumor grade in clinical trials

1

List of publications

Original articles

1. Goldhirsch A. Ammoniemia nelle epatopatie acute. Tesi di Laurea. Gior Mal Infettive Parassit 26: 1139-45, 1974

2. Milazzo F, Lorenzelli A, Vigevani GM, Resta M, Goldhirsch A. La dialisi peritoneale nel trattamento dell'encefalopatia epatica. Gior Mal Infettive Parassit 26: 1159-63, 1974

3. Resta M, Vigevani GM, Goldhirsch A, Milazzo F. Epatite e droga. Gior Mal Infettive e Parassit 26: 1289-97, 1974

4. Cavalli F, Pedrinis E, Ludin J, Goldhirsch A, Tatti V. Die prolymphozytäre Leukämie: Eine neue klinische Entität. Dtsch med Wschr 102: 1443-45, 1977

5. Cavalli F, Pedrinis E, Mombelli G, Goldhirsch A, Reiner M. Knochendestruktionsherde als Vorläufer des Blastenschubes bei einer chronischen myeloischen Leukämie. Schweiz med Wschr 107: 872-75, 1977

6. Cioccari L, Goldhirsch A, Cavalli F. Präliminäre Ergebnisse einer Phase II Studie mit DDP (Cis-diammin-dichlor-platinum) beim kleinzelligen Bronchuskarzinom. Schweiz med Wschr 109: 845-47, 1979

7. Reiner M, Goldhirsch A, Luscietti PR, Pedrinis E, Kaplan E, Cavalli F. Association of Warthin's tumor with Sjögren Syndrome and malignant non-Hodgkin's lymphoma. Ear, Nose Throat J 58: 345-50, 1979

8. Reiner M, Goldhirsch A, Kaplan E, Luscietti PR, Pedrinis E, Noseda G. Ungewöhnliche autoimmune und neoplastische Begleiterkrankungen bei Sjögren-Syndrom. Schweiz med Wschr 109: 1741-42, 1979

9. Cavalli F, Goldhirsch A, Siegenthaler P, Kaplan S, Beer M. Phase II study with cis-dichlordiammineplatinum(II) in small cell anaplastic bronchogenic carcinoma. Eur J Cancer Clin Oncol 16: 617-21, 1980

10. Goldhirsch A, Pirovino M, Sonntag RW, Tschopp L, Ryssel HJ, Brunner KW. Combination chemotherapy with VM-26, adriamycin, bleomycin and prednisone as a secondary treatment of malignant lymphoma. Cancer Treat Rep 64: 335-37, 1980

11. Goldhirsch A, Joss R, Sonntag RW, Brunner KW. Vindesin, ein neues Zytostatikum aus der Reihe der Vinca-Alkaloide. Dtsch med Wschr 105: 931-35, 1980

12. Goldhirsch A, Beer M, Sonntag RW, Tschopp L, Cavalli F, Ryssel HJ, Brunner KW. Phase II Studie mit Vindesin bei fortgeschrittenen malignen Erkrankungen. Schweiz med Wschr 110: 1063-67, 1980

13. Goldhirsch A, Pirovino M, Coninx S, Tschopp L, Sonntag RW. Acute erythroleukemia following chemotherapy for Hodgkin's disease. Am J Med Sci 280: 53-56, 1980

14. Tieche M, Goldhirsch A, Brunner KW. Adjuvante Chemotherapie bei Weichteilsarkomen. Schweiz med Wschr 110: 374-79, 1980

15. Cavalli F, Rozencweig M, Renard J, Goldhirsch A, Hansen HH. Phase II study of oral VP-16-213 in hepatocellular carcinoma. Eur J Cancer Clin Oncol 17: 1079-82, 1981

16. Goldhirsch A, Joss R, Cavalli F, Sonntag RW, Ryssel HJ, Brunner KW. Cis-Dichlordiammineplatinum (II) and VP-16-213 combination chemotherapy for non-small cell lung cancer. Med Pedr Oncol 9: 205-208, 1981

2

17. Joss R, Goldhirsch A, Cavalli F, Weber W, Kaplan S, Obrecht JP, Sonntag RW, Brunner KW. Chemotherapie des nicht-kleinzelligen Bronchuskarzinom mit einer Kombination von Cis-Diamminedichlor-platinum(II) und VP-16-213. Schweiz med Wschr 111: 1331-1334, 1981

18. Goldhirsch A, Joss R, Leuenberger U, Cavalli F, Ryssel HJ, Brunner KW. An evaluation of tamoxifen dose escalation in advanced breast cancer. Am J Clin Oncol (CCT) 5: 501-503, 1982

19. Goldhirsch A, Joss R, Cavalli F, Brunner KW. Etoposide as single agent and in combination chemotherapy of bronchogenic carcinomas. Cancer Treat Rev 9: 85-90, 1982

20. Goldhirsch A, Leuenberger U, Ryssel HJ, Cavalli F, Sonntag RW, Joss R, Brunner KW. Combination hormonotherapy with tamoxifen and fluoxymestrone in patients with advanced breast cancer relapsing on hormonotherapy. Oncology 39: 284-86, 1982

21. Goldhirsch A, Kiser J, Joss R, Jungi E, Salchli S, Sonntag RW, Tschopp L, Gervasi A, Brunner KW. Verhinderung des zytostatikabedingten Haarausfalls durch Hypothermie der behaarten Kopfhaut mittels einer Kühlkappe. Schweiz med Wschr 112: 568-71, 1982

22. Greiner R, Goldhirsch A, Joss R, Dreher E, Locher G, Veraguth P, Brunner KW. Postoperatives Behandlungskonzept des Ovarialkarzinoms: Technik, Bedeutung und Grenzen der Strahlentherapie. Strahlentherapie 158: 653-58, 1982

23. Joss R, Galeazzi R, Bischoff A, Do DD, Goldhirsch A, Brunner KW. Levonantradol, a new antiemetic with high rate of side effects for the prevention of nausea and vomiting in patients receiving cancer chemotherapy. Cancer Chemotherapy Pharmacol 9: 61-64, 1982

24. Joss R, Brunner KW, Goldhirsch A. Mitomycin, hexamethylmelamine, and vindesine as second-line treatment for small cell cancer of the lung. Cancer Treat Rep 66: 1873-74, 1982

25. Tamassia V, Battaglia A, Ganzina F, Isetta AM, Sacchetti G, Cavalli F, Goldhirsch A, Brunner KW, Bernardo G, Robustelli della Cuna G. Pharmacokinetic approach to the selection of dose schedules for medroxyprogesterone acetate in clinical oncology. Cancer Chemother Pharmacol 8: 151-56, 1982

26. Zava DT, Wyler-Von Ballmoos A, Goldhirsch A, Roos W, Takahashi A, Eppenberger U. A quality control study to assess inter-laboratory variability of routine estrogen and progesterone receptor assays. Eur J Cancer Clin Oncol 18: 713-21, 1982

27. Cavalli F, Pedrazzini A, Martz G, Jungi WF, Brunner KW, Goldhirsch A, Mermillod B, Alberto P. Randomized trial of 3 different regimens of combination chemotherapy in patients receiving simultaneously a hormonal treatment for advanced breast cancer. Eur J Cancer Clin Oncol 19: 1615-24, 1983

28. Goldhirsch A, Joss R Markwalder TM, Studer H, Brunner KW. Acute cerebrovascular accident after treatment with cis-platinum and methylprednisolone. Oncology 40: 344-45, 1983

29. Goldhirsch A, Triller JK, Greiner R, Dreher E, Davis B. Computed tomography prior to second-look operation in advanced ovarian cancer. Obstet Gynecol 62: 630-34, 1983

30. Herrmann U, Dreher E, Goldhirsch A, Locher G, Jann FX. Ultraschalldiagnose des Ovarialkarzinoms. Schweiz med Wschr 113: 1544-49, 1983

31. Joss R, Kaplan S, Goldhirsch A, Varini M, Brunner KW, Cavalli F. A phase I trial of marcellomycin with weekly dose schedule. Eur J Cancer Clin Oncol 19: 455-59, 1983

32. Joss R, Gervasi A, Goldhirsch A, Brunner KW. Hochdosiertes Methylprednisolon als Antiemetikum beim zytostatika-bedingten Erbrechen. Schweiz med Wschr 113: 426-29, 1983

33. Ludwig Breast Cancer Study Group (A. Goldhirsch, Study Coordinator). Toxic effects of early adjuvant chemotherapy for breast cancer. Lancet ii: 542-44, 1983

3

34. Markwalder TM, Zava DT, Goldhirsch A, Markwalder RV. Estrogen and progesterone receptors in meningiomas in relation to clinical and pathologic features. Surg Neurol 20: 42-47, 1983

35. Verdon B, Berger EG, Salchli S, Goldhirsch A, Gerber A. An enzyme-linked immunosorbent assay for lactose synthase (galactosyl-transferase) in serum and its application as a tumor marker in ovarian carcinoma. Clin Chem 29: 1928-33, 1983

36. Zava DT, Goldhirsch A. Estrogen receptor in malignant melanoma. Fact or artefact? Eur J Cancer Clin Oncol 19: 1151-59, 1983

37. Davis B, Zava DT, Locher G, Goldhirsch A, Hartmann WH. Receptor heterogeneity of human breast cancer as measured by multiple intratumoral assays of estrogen and progesterone receptor. Eur J Cancer Clin Oncol 20: 375-82, 1984

38. Triller J, Goldhirsch A. Computertomographie, primäre Laparotomie und second-look Operation beim Ovarialkarzinom. Fortschr Roentgenstr 3: 294-303, 1984

39. Cavalli F, Goldhirsch A, Jungi WF, Martz G, Mermillod B, Alberto P, for the Swiss Group for Clinical Cancer Research. Randomized trial of low-versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer. J Clin Oncol 2: 414-19, 1984

40. Davis BW, Berger EG, Locher GW, Zeller M, Goldhirsch A. Immuno-histochemical localization of galactosyltransferase in the normal human ovary and fallopian tube. J Histochem Cytochem 32: 92-96, 1984

41. Davis BW, Goldhirsch A, Locher GW, Dreher E, Greiner R, Bürki K, Brunner KW. Pathologic data of prognostic significance for remission induction in advanced ovarian carcinoma. J Cancer Res Clin Oncol 107: 106-110, 1984

42. Greiner R, Goldhirsch A, Davis B, Dreher E, Peyer T, Locher G, Neuenschwander H, Joss R, Brunner KW, Veraguth P. Whole-abdominal radiation in patients with advanced ovarian carcinoma after surgery. J Cancer Res Clin Oncol 107: 94-98, 1984

43. Joss RA, Kaplan S, Goldhirsch A, Sessa C, Brunner KW, Cavalli F. A phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five weeks-schedule. Invest New Drugs 2: 297-304, 1984

44. Locher GW, Davis B, Zava DT, Goldhirsch A, Hartmann WA. Intratumorale regionäre Unterschiede im Hormonrezeptor-Status des Mammakarzinoms. Geburtsh u Frauenheilk 44: 304-306, 1984

45. Ludwig Breast Cancer Study Group (A. Goldhirsch, Study Coordinator). Randomized trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet i: 1256-1260, 1984

46. Triller J, Goldhirsch A, Fuchs WA. Wertigkeit der Computertomographie in der Beurteilung von Lymphknotenmetastasen beim Ovarialkarzinom. Fortschr Roentgenstr 141: 35-39, 1984

47. Joss RA, Alberto P, Obrecht JP, Barrelet L, Holdener EE, Siegenthaler P, Goldhirsch A, Mermillod B, Cavalli F (for the SAKK). Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide. Cancer Treat Rep 68: 1079-84, 1984

48. Alberto P, Mermillod B, Kaplan E, Goldhirsch A, Obrecht JP, Jungi WF, Martz G, Barrelet L, Cavalli F. A clinical trial of aminoglutethimide in advanced postmenopausal breast carcinoma: low response in patients previously treated with medroxy-progesterone. Eur J Cancer Clin Oncol 21: 423-28, 1985

4

49. Davis BW, Gelber RD, Goldhirsch A, Hartmann WH, Hollaway L, Russel I, Rudenstam CM, for the Ludwig Breast Cancer Study Group. Prognostic significance of peritumoral vessel invasion in adjuvant treated breast cancer with axillary lymph node metastasis. Hum Pathol 16: 1212-18, 1985

50. Goldhirsch A, Greiner R, Dreher E, Locher G, Davis B, Reinhard JP, Brunner KW. The treatment of ovarian cancer by a multimodality approach: remission induction with chemotherapy - Hexa-PAMP and PAMP regimens- followed by whole-abdominal radiation. Onkologie 8: 383-87, 1985

51. Greiner R, Goldhirsch A, Dreher E, Locher G Jeanneret C, Meister A, Mihic N, Veraguth P. Die Ganzabdomenbestrahlung nach Kombinations-Chemotherapie und second-look Laparotomie bei der Behandlung des fortgeschrittenen Ovarialkarzinoms. Onkologie 8: 364-72, 1985

52. Ludwig Breast Cancer Study Group, (A. Goldhirsch, Study Coordinator). Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer. J Clin Oncol 3: 1059-67,1985

53. Ludwig Breast Cancer Study Group, (A. Goldhirsch, Study Coordinator). A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Res 45: 4454-59, 1985

54. Meier C, Goldhirsch A, Hess C, Bazarian J, Greiner R, Beer M. Polyneuropathie nach Cisplatin-Behandlung. Dtsch med Wschr 18: 721-25, 1985

55. Triller J, Goldhirsch A, Reinhard JP. Subcapsular liver metastasis in ovarian cancer: computed tomography and surgical staging. Eur J Radiol 5: 261-66, 1985

56. Goldhirsch A, Greiner R, Bleher A, Jeschko M, Dreher E, Krauer F, Cavalli F. Combination of chemotherapy with methotrexate, bleomycin and cis-platinum, and radiation therapy for locally advanced carcinoma of the cervix. Am J Clin Oncol 9: 12-14, 1986

57. Pedrazzini A, Gelber RD, Isley M, Castiglione M, Goldhirsch A. First repeated bone scan in the follow-up of patients with operable breast cancer. J Clin Oncol 3: 389-94, 1986

58. Goldhirsch A, Gelber RD for the Ludwig Breast Cancer Study Group. Adjuvant treatment for early breast cancer: the Ludwig Breast Cancer Studies. Natl Cancer Inst Monogr 1: 55-70, 1986

59. Joss RA, Ryssel HJ, Bischoff AK, Goldhirsch A, Brunner KW. Abbreviated phase I clinical trial of i.v. mitozolomide. Cancer Treat Rep 70: 797-98, 1986

60. Davis BW, Gelber RD, Goldhirsch A, Hartmann, Locher GW, Reed R, Golouh R, Säve-Söderbergh J, Hollaway L, Russel I, Rudenstam CM, for the Ludwig Breast Cancer Study Group. Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer 58: 2662-70, 1986

61. Gelber RD, Goldhirsch A. A new endpoint for assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 4: 1772-1779, 1986

62. Gelber RD, Goldhirsch A. The concept of an overview of cancer clinical trials with special emphasis on early breast cancer. J Clin Oncol 4: 1696-703, 1986

63. Pedrazzini A, Cavalli F, Brunner KW, Goldhirsch A, Mermillod B. Complete remission following endocrine or combined cytotoxic and hormonal treatment in advanced breast cancer. Oncology 44: 51-59, 1987

5

64. Gelber RD, Goldhirsch A. Interpretation of results from subset analyses within overviews in randomized clinical trials. Stat Med 6: 371-88, 1987

65. Herrmann jr UJ, Locher GW, Goldhirsch A. Sonographic patterns of ovarian tumors: prediction of malignancy. Obstet Gynecol 5: 777-81, 1987

66. Goldhirsch A, Gelber RD, Castiglione M. Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: Patterns and prognoses. J Clin Oncol 6: 89-97, 1988

67. Goldhirsch A, Berger E, Müller O, Maibach R, Misteli S, Buser K, Rösler H, Brunner KW. Ovarian cancer and tumor markers: Sialic acid, galactosyltransferase, and CA-125. Oncology 45: 281-86, 1988

68. Goldhirsch A, Greiner R, Dreher E, Sessa C, Krauer F, Forni M, Jungi FW, Brunner KW, Veraguth P, Engeler V, Leyvraz S, Siegenthaler P, Gloor E, Buser K, Gelber RD, Cavalli F. Treatment of advanced ovarian cancer with surgery, chemotherapy and consolidation of response by whole-abdominal radiation. Cancer 62: 40-47, 1988

69. Ludwig Breast Cancer Study Group (A. Goldhirsch, Study Coordinator). On the safety of perioperative adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil in breast cancer. Eur J Cancer Clin Oncol 24: 1305-308, 1988

70. Ludwig Breast Cancer Study Group (A. Goldhirsch Study Coordinator). Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle. N Engl J Med 319: 677-83, 1988

71. Goldhirsch A, Gelber RD, Castiglione M. Chemohormonal therapy of operable breast cancer. Cancer Investigation 6: 558-60, 1988

72. Goldhirsch A, Gelber RD, Simes RJ, Glasziou P, Coates AS, for the Ludwig Breast Cancer Study Group. Costs and benefits of adjuvant therapy in breast cancer: A quality-adjusted survival analysis. J Clin Oncol 7: 36-44, 1989

73. Ludwig Breast Cancer Study Group (A. Goldhirsch, Study Coordinator). Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 320: 491-96, 1989

74. Gelber RD, Gelman RS, Goldhirsch A. A quality-of-life-oriented endpoint for comparing therapies. Biometrics 45: 781-795, 1989

75. Gelber RD, Goldhirsch A. Comparison of adjuvant therapies using quality-of-life considerations. Intl J of Technology Assessment in Health Care 5: 401-13, 1989

76. The International Breast Cancer Study Group (A. Goldhirsch. Study Coordinator). Late effects of adjuvant oophorectomy and chemotherapy upon pre-menopausal breast cancer patients. Ann Oncol 1: 30-35, 1990

77. Castiglione M, Gelber RD, Goldhirsch A. Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality. J Clin Oncol 8: 519-26, 1990

78. Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. Ann Oncol 1: 183-88, 1990

79. International (Ludwig) Breast Cancer Study Group (Goldhirsch A, Study Coordinator). Prognostic importance of occult axillary lymph node micrometastases from breast cancer. Lancet 335: 1565-68, 1990

6

80. Richner J, Gerber HA, Locher GW, Goldhirsch A, Gelber RD, Gullick WJ, Berger MS, Groner B, Hynes NE. C-erbB-2 protein expression in node negative breast cancer. Ann Oncol 1: 263-68,1990

81. Beretta KR, Höffken K, Kvinnsland S, Trunet P, Chaudri HA, Bhatnagar AS, Goldhirsch A, Cavalli F. CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer - A phase I study. Ann Oncol 1: 421-26, 1990

82. Gelber RD, Goldhirsch A, Cavalli F, for the International Breast Cancer Study Group. Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. Ann Intern Med 114: 621-28, 1991

83. Anbazaghan R, Gelber RD, Bettelheim R, Goldhirsch A, Gusterson BA. Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer. Ann Oncol 2: 47-53, 1991

84. Sessa C, Goldhirsch A, Martinelli G, Alerci M, Imburgia L, Cavalli F. Phase I study of the combination of monthly carboplatin and weekly cisplatin. Ann Oncol 2: 123-29, 1991

85. Cerny T, Martinelli G, Goldhirsch A, Terrier F, Joss R, Fey MF, Brunner KW, Küpfer A. Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study. J Cancer Res Clin Oncol 117: S135-S138, 1991

86. Neville AM, Bettelheim R, Gelber RD, Säve-Söderbergh J, Davis BW, Reed R, Torhorst J, Golouh R, Peterson HF, Price KN, Isely M, Rudenstam C-M, Collins J, Castiglione M, Senn H-J, Goldhirsch A, for the International (Ludwig) Breast Cancer Study Group: Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. J Clin Oncol, 10: 696-705, 1992

87. Gelber RD, Goldhirsch A, for the International Breast Cancer Study Group: Reporting and interpreting adjuvant clinical trials. J Natl Cancer Inst Monogr 11: 59-69, 1992

88. Goldhirsch A, Castiglione M, Gelber RD, for the International Breast Cancer Study Group. A single perioperative adjuvant chemotherapy course for node-negative breast cancer: five-year results of trial V. J Natl Cancer Inst Monogr 11: 86-96 1992

89. Gelber RD, Goldhirsch A, Hürny C, Bernhard J, Simes J, for the International Breast Cancer Study Group: Quality of life in clinical trials of adjuvant therapies. J Natl Cancer Inst Monogr 11: 127-35, 1992

90. Hürny C, Bernhard J, Gelber RD, Coates A, Castiglione M, Isley M, Dreher D, Peterson H, Goldhirsch A, Senn H-J for the International Breast Cancer Study Group: Quality of life measures for patients receiving adjuvant therapy for breast cancer: an international trial. Eur J Cancer 28: 118-24, 1992

91. Gelber RD, Lenderking WR, Cotton DJ, Cole BF, Fischl MA, Goldhirsch A, Testa MA for the AIDS Clinical Trials Group. Quality-of-life evaluation in a clinical trial of zidovudine therapy in patients with mildly symptomatic human immunodeficiency virus type 1 HIV infection. Ann Intern Med 116: 961-66, 1992

92. Richner J, Joss RA, Goldhirsch A, Brunner KW. Phase II study of continuous subcutaneous interferon-alfa combined with cisplatin in advanced malignant melanoma. Eur J Cancer 28A: 1044-47, 1992

93. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Säve-Söderborgh, Anbazhagan R, Styles J, Rudenstam C-M, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Bürki K, Castiglione M, Collins J, Lintner J, Senn H-J, for the International (Ludwig) Breast Cancer Study Group. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10: 1049-56, 1992

7

94. Glick JH, Gelber RD, Goldhirsch A, Senn HJ. Meeting highlights: Adjuvant therapy of primary breast cancer. J Natl Cancer Inst 84: 1479-85, 1992

95. Spataro V, Price K, Goldhirsch A, Cavalli F, Simoncini E, Castiglione M, Rudenstam C-M, Collins J, Lindtner J, Gelber RD. Sequential estrogen receptor determinations from breast cancer and at relapse: prognostic and therapeutic relevance. Ann Oncol 3: 733-40, 1992

96. Hürny Ch, Bernhard J, Bacchi M, van Wegberg B, Tomamichel M, Spek U, Coates A, Castiglione M, Goldhirsch A, Senn H-J, and the International Breast Cancer Study Group. The perceived adjustment to chronic illness scale (PACIS): a global indicator of coping for operable breast cancer patients in clinical trials. Support Care Cancer 1: 200-208, 1993

97. Castiglione-Gertsch M, Pampallona S, Varini M, Cavalli F, Brunner K, Senn H-J, Goldhirsch A, Metzger U. Primary endocrine therapy for advanced breast cancer: To start with tamoxifen or with medroxyprogesterone acetate? Ann Oncol 4: 735-40, 1993

98. Gelber RD, Goldhirsch A, Cole BF for the International Breast Cancer Study Group. Parametric extrapolation of survival estimates with applicattions to quality of life evaluation of treatments. Controlled Clinical Trials 14: 485-99, 1993

99. Cole BF, Gelber RD, Goldhirsch A. Cox regression models for quality adjusted survival analysis. Stat in Med 12: 975-87, 1993

100. Hürny Ch, Bernhard J, Coates A, Castiglione M, Peterson H.F, Gelber R.D, Rudenstam C.-M, Goldhirsch A, Senn H.J. and the International Breast Cancer Study Group. Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: its effect on patient self-estimation. Ann Oncol 5: 65-74, 1994

101. Goldhirsch A, Gelber RD, Price KN, Castiglione M, Coates AS, Rudenstam C.-M, Collins J, Lindtner J, Hacking A, Marini G, Byrne M, Cortés-Funes H, Schnürch G, Brunner KW, Tattersall MHN, Forbes J, Senn H.-J. Effect of systemic adjuvant treatment on first site of breast cancer relapse. Lancet 343: 377-81, 1994

102. Lenderking WR, Gelber RD, Cotton DJ, Cole BF, Goldhirsch A, Volberding PA, Testa MA for the AIDS Clinical Trials Group. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. N Engl J Med 330: 738-43, 1994

103. Nathan B, Gusterson B, Jadayel D, O'Hare M, Anbazhagan R, Jayatilake H, Ebbs S, Micklem K, Price K, Gelber R, Reed R, Senn H.-J, Goldhirsch A, Dyer MJS, for the International (Ludwig) Breast Cancer Study Group. Expression of BCL-2 in primary breast cancer and its correlation with tumour phenotype. Ann Oncol 5: 409-14, 1994

104. Goldhirsch A, Gelber RD, Castiglione M, Price KN, Rudenstam C.-M, Lindtner J, Collins J, Senn H.-J, Brunner KW, Galligioni E, Cavalli F, Gudgeon A, Cortes-Funes H, Tattesall M, Marini G, Byrne M, Snyder R, Forbes J, Hürny C, Coates A, for the International Breast Cancer Study Group. Present and future projects of the International Breast Cancer Study Group. Cancer 74: 1139-49, 1994

105. Borner M, Bacchi M, Goldhirsch A, Greiner R, Harder F, castiglione M, Jungi WF, Thürlimann B, Cavalli F, Obrecht JP, Leyvraz S, Alberto P, Adam H, varini M, Loehnert T, Senn HJ, Metzger U, Brunner K for the Swiss Group for Clinical cancer Research. First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. J Clin Oncol 12: 2071-77, 1994

106. Castiglione-Gertsch M, Johnsen C, Goldhirsch A, Gelber RD, Rudenstam CM, Collins J, Lindtner J, Hacking A, Cortes-Funes H, Forbes J, Simpson J, Tattersall MHN, Brunner K, Cavalli F, Senn HJ for the International Breast Cancer Study Group. The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up. Ann Oncol 5: 717-24, 1994

8

107. Swiss Group for Clinical Cancer Research (SAKK; writing committee: U. Laffer, U. Metzger, P. Aeberhard, R. Maibach, M. Castiglione, A. Goldhirsch). Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Lancet 345: 349-53, 1995

108. Goldhirsch A, Gelber RD, Castiglione M, Price KN, Rudenstam C.-M, Lindtner J, Collins J, Senn H.-J, Cavalli F, Galligioni E, Fey M, Gudgeon A, Cortes-Funes H, Tattesall M, Marini G, Byrne M, Snyder R, Forbes J, Kay R, Hürny C, Thürlimann B, Reed R, Gusterson B, Torhorst J, Säve-Soderbergh, Coates A, for the International Breast Cancer Study Group. Present and future projects of the International Breast Cancer Study Group. Isr J Med Sci 31: 144-54, 1995

109. Sessa C, Pagani O, Parma G, Goldhirsch A, Cavalli F. Dose-finding study of paclitaxel and cyclophosphamide in patients with advanced breast cancer. Semin Oncol 22 (Suppl 6): 112-17, 1995

110. Gelber RD, Cole BF, Goldhirsch A, Bonadonna G, Howell A, McArdle CS, Mouridsen HT, Rubens RD, Welvaart K. Adjuvant chemotherapy for premenopausal breast cancer. A meta-analysis using quality-adjusted survival. Cancer J Sci Am 1: 114-21, 1995

111. Goldhirsch A, Wood WC, Senn H.-J, Glick JH, Gelber RD. Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 87: 1441-45, 1995

112. Crivellari D, Price KN, Hagen M, Goldhirsch A, Gelber RD, Castiglione M, Coates AS, Rudenstam C.-M, Collins J, Lintner J, Cortes-Funes H, Gudgeon A, Simoncini E, Byrne M, Schnürch HG, Fey M, Tattesall MHN, Forbes JF, Cavalli F, Reed R, & Senn HJ. Routine tests during follow-up of patients after primary treatment for operable breast cancer. Ann Oncol 6: 769-77, 1995

113. Buser K, Bacchi M, Goldhirsch A, Greiner R, Diener P, Sessa C, Jungi WF, Forni M, Leyvraz S, & Engeler V, for the Swiss Group of Clinical Cancer Research (SAKK). Treatment of ovarian cancer with surgery, short-course chemotherapy and whole abdominal radiation. Ann Oncol 7: 65-70, 1996

114. Saletti P, Bolognini G, Pagani O, Goldhirsch A. Acido 13-cis-retinoico e interferone alfa 2a nel trattamento della papillomatosi tracheobronchiale recidivante. Tribuna Medica Ticinese 60: 19-20, 1996

115. Marini M, Murray S, Goldhirsch A, Gelber RD, Castiglione-Gertsch M, Price KN, Tattersall MHN, Rudenstam C-M, Collins J, Lindtner J, Cavalli F, Cortés-Funes H, Gudgeon A, Forbes JF, Galligioni E, Coates AS, Senn H-J The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. Ann Oncol 7: 245-50, 1996

116. Gelber RD, Cole BF, Goldhirsch A, Rose C, Fisher B, Osborne CK, Boccardo F, Gray R, Gordon NH, Bengtsson N-O, Sevelda P. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: a meta-analysis using quality-adjusted survival. Lancet 347: 1066-71, 1996

117. Hürny C, Bernhard J, Coates A, Peterson HF, Castiglione-Gertsch M, Gelber RD, Rudenstam C.-M, Collins J, Lindtner J, Goldhirsch A, Senn H.-J. Responsiveness of a single-item indicator versus multi-item scale. Assessment of emotional well-being in an international breast cancer trial. Med Care 34: 234-48, 1996

118. Hürny C, Bernhard J, Coates AS, Castiglione-Gertsch M, Peterson HF, Gelber RD, Forbes JF, Rudenstam CM, Simoncini E, Crivellari D, Goldhirsch A, Senn HJ. Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group. Lancet 347: 1279-84, 1996

119. International Breast Cancer Study Group (M. Castiglione-Gertsch, A. Goldhirsch, Study Coordinators). Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol 14: 1885-94, 1996

9

120. Thürlimann B, Beretta K, Bacchi M, Castiglione-Gertsch M, Goldhirsch A, Jungi WF, Cavalli F, Senn H-J, Fey M, Löhnert T. First-line fadrozole HCl (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomized trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann Oncol 7: 471-79, 1996

121. Gelber RD, Goldhirsch A, Cole BF, Weiand HS, Schroeder G, Krook JE. A Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. J Natl Cancer Inst 88: 1039-45, 1996

122. Colombo T, Gonzalez Paz O, Zucchetti M, Maneo M, Sessa C, Goldhirsch A, D'Incalci M. Paclitaxel induces significant changes in epidoxorubicin distribution in mice. Ann Oncol 7: 801-05, 1996

123. Regazzoni S, Pesce G, Marini G, Cavalli F, Goldhirsch A. Low-dose continuous infusion of 5-fluorouracil for metastatic breast cancer. Ann Oncol 7: 807-13, 1996

124. Wallgren A, Bernier J, Gelber RD, Goldhirsch A, Roncadin M, Joseph D, Castiglione-Gertsch M, for the IBCSG. Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer. Int J Radiat Oncol Biol Phys 35: 649-59, 1996

125. Cole BF, Gelber RD, Kirkwood JM, Goldhirsch A, Barylak E, Borden E. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group Study. J Clin Oncol 14: 2666-73, 1996

126. Regazzoni S, Marini G, Grob A, Pedrazzini A, Goldhirsch A, Castelli D, Cavalli F, Ghielmini M. High-dose chemotherapy with autologous stem cell transplantation is feasible and safe in a regional hospital. A 6-year experience in southern Switzerland. Bone Marrow Transplant. 19: 3-7, 1997

127. International Breast Cancer Study Group (M. Castiglione-Gertsch, A. Goldhirsch, Study Coordinators). Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol 15: 1385-94, 1997

128. Pestalozzi BC, Peterson HF, Gelber RD, Goldhirsch A, Gusterson BA, Trihia H, Lindtner J, Cortes-Funes H, Simoncini E, Byrne M, Golouh R, Rudenstam C-M, Castiglione-Gertsch M, Allegra CJ, Johnston PG. Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol 15: 1923-31, 1997

129. Thürlimann B, Castiglione M, Hsu-Schmitz SF, Cavalli F, Bonnefoi H, Fey MF, Morant R, Löhnert T, Goldhirsch A for the Swiss Group for Clinical Cancer Research (SAKK). Formestane versus megestrol acetate in postmenopausal breast cancer patientrs after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Eur J Cancer 33: 1017-24, 1997

130. Clahsen PC, van de Velde CJH, Goldhirsch A, Rossbach J, Sertoli MR, Bijnens L, Sylvester R. Overview of randomized perioperative polychemotherapy trials in women with early-stage breast cancer. J. Clin Oncol 15: 2526-35, 1997

131. Pagani O, Sessa C, Martinelli G, Cerny T, de Jong J, Goldhirsch A. Zimatore M, Cavalli F. Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer. Ann Oncol 8: 655-61, 1997

132. Goldhirsch A, Gelber RD, Castiglione M, O’Neill A, Thürlimann B, Rudenstam C.-M, Lindtner J, Collins J, Forbes J, Crivellari D, Coates A, Cavalli F, Simoncini E, Fey MF, Pagani O, Price K, Senn H.-J, and other members of the International Breast Cancer Study Group. Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: Results of the International Breast Cancer Study Group (IBCSG) Trial VI. Ann Oncol 8: 751-56, 1997

133. Bernhard J, Hürny C, Coates AS, Peterson HF, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Senn H.-J, Rudenstam C.-M for the International Breast Cancer Study Group. Quality of life

10

assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. Ann Oncol 8: 825-35, 1997

134. Nolè F, de Braud F, Aapro M, Minchella I, De Pas M, Zampino MG, Monti S, Andreoni G, Goldhirsch A. Phase I-II study of vinorelbine in combination with 5-FU and folinic acid as first line chemotherapy in metastatic breast cancer. A regimen with a low subjective toxic burden. Ann Oncol 8: 865-70, 1997

135. Sessa C, Pagani O, Martinelli G, Cerny T, de Jong J, Goldhirsch A, Zimatore M, Cavalli F. Dose-finding study of paclitaxel and cyclophosphamide in women withadvanced breast cancer. Semin Oncol 17(Suppl 5): S52-57, 1997

136. The Swiss Group for Clinical Cancer Research (SAKK) (Laffer U, Harder F, Jäggi P, Maibach R, Hsu-Schmitz SF, Metzger U, Castiglione M, Goldhirsch A, et al). Association between blood transfusion and survival in a randomized multicentre trial of perioperative adjuvant portal chemotherapy in patients with colorectal cancer. Eur J Surg 163: 693-701, 1997

137. Castiglione-Gertsch M, Tattersall M, Hacking A, Goldhirsch A, Gudgeon A, Gelber RD, Lindtner J, Coates A, Collins J, Isley M, Senn HJ, Rudenstam CM. Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group. Eur J Cancer 33: 2321-25, 1997

138. Goldhirsch A, Coates AS, Colleoni M, Castiglione-Gertsch M, and Gelber RD, for the International Breast Cancer Study Group. Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. J Clin Oncol 16: 1358-62, 1998

139. Borner MM, Castiglione M, Bacchi M, Weber W, Herrmann R, Fey MF, Pagani O, Leyvraz S, Morant R, Pestalozzi B, Hanselmann S, Goldhirsch A for the Swiss Group for Clinical Cancer Research (SAKK). The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: Results of a phase III trial. Ann Oncol 9: 535-41, 1998

140. Pagani O, O'Neill A, Castiglione M, Gelber RD, Goldhirsch A, Rudenstam C.-M, Lindtner J, Collins J, Crivellari D, Coates A, Cavalli F, Thürlimann B, Simoncini E, Fey M, Price K, Senn H.J. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the international Breast Cancer Study Group (IBCSG) trial VI. Eur J Cancer 34, 632-40, 1998

141. Colleoni M. Nole' F, Minchella I, Noberasco C, Luini A, Orecchia R, Veronesi P, Zurrida S, Viale G, Goldhirsch A. Pre-operative chemotherapy and radiotherapy in breast cancer. Eur J Cancer 34, 641-45, 1998

142. Cole BF, Solal-Céligny P, Gelber RD, Lepage E, Gisselbrecht C, Reyes F, Sebban C, Sugano D, Tendler C, and Goldhirsch A. Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: An aid to clinical decision making. J Clin Oncol 16: 2339-44, 1998

143. Colleoni M, Martinelli G, Beretta F, Marone C, Gallino A, Fontana M, Graffeo R, Zampino G, De Pas T, Cipolla G, Martinoni C, and Goldhirsch A. Intracavitary chemotherapy with thiotepa in malignant pericardial effusions: An active and well-tolerated regimen. J Clin Oncol 16: 2371-76, 1998

144. Biffi R, de Braud F, Orsi F, Pozzi S, Mauri S, Goldhirsch A, Nolè F, Andreoni B. Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days. Ann Oncol 9: 767-73, 1998

145. Bernhard J, Hurny C, Coates AS, Peterson HF, Castiglione-Gertsch M, Gelber RD, Galligioni E, Marini G, Thurlimann B, Forbes JF, Goldhirsch A, Senn H-J, Rudenstam CM. Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group. Br J Cancer 78: 686-93, 1998

11

146. Jungi WF, Bernhard J, Hsu-Schmitz S-F, Hanselmann S, Gusset H, Pestalozzi D, Goldhirsch A, for the Swiss Group for Clinical Cancer Research (SAKK). Effect of carboplatin on response and palliation in hormone-refractory prostate cancer. Support Care Cancer 6: 462-68, 1998

147. Pinder SE, Murray S, Ellis IO, Trihia H, Elston CW, Gelber RD, Goldhirsch A, Lindtner J, Cortes-Funes H, Simoncini E, Byrne MJ, Golouh R, Rudenstam CM, Castiglione-Gertsch M, Gusterson BA. The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy. Cancer 83: 1529-39, 1998

148. Goldhirsch A, Glick JH, Gelber RD, Senn H.-J. Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 90: 1601-608, 1998

149. De Pas T, De Braud F, Orlando L, Nole F, Munzone E, Zampino MG, Fazio N, Aapro MS, Goldhirsch A. High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? Ann Oncol 9: 917-19, 1998

150. Colleoni M, Price K, Castiglione-Gertsch M, Goldhirsch A, Coates A, Lintner J, Collins J, Gelber RD, Thürlimann B, Rudenstam CM and members of the International Breast Cancer Study Group. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. Eur J Cancer 34: 1693-700, 1998

151. Colleoni M, Orvieto E, Nolé F, Orlando L, Minchella I, Viale G, Peruzzotti G, Robertson C, Noberasco C, Galimberti V, Sacchini V, Veronesi P, Zurrida S, Orecchia R, and Goldhirsch A. Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer 35: 574-79, 1999

152. Sabbioni ME, Castiglione M, Hürny C, Siegrist HP, Bacchi M, Bernhard J, Thürlimann B, Bonnefoi H, Perey L, Goldhirsch A, Senn HJ. Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients. Support Care Cancer 7: 149-53, 1999

153. Pagani O, Sessa C, Martinelli G, Crivellari D, Buonadonna A, Thürlimann B, Hess D, Borner M, Bauer J, Zampino G, Zimatore M, Graffeo R, Riva A, Goldhirsch A. Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Ann Oncol 10: 539-45, 1999

154. Colombo T, Parisi I, Zucchetti M, Sessa C, Goldhirsch A, D'Incalci M. Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin. Ann Oncol 10: 391-95,1999

155. Bernhard J, Castiglione-Gertsch M, Hsu Schmitz S-F., Thürlimann B, Cavalli F, Morant R, Fey MF, Bonnefoi H, Goldhirsch A, Hürny C. Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Eur J Cancer 35: 913-20, 1999

156. Colleoni M, Price KN, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A, for the International Breast Cancer Study Group. Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil. Lancet 354: 130-31, 1999

157. Bertolini F, Paolucci M, Peccatori F, Cinieri S, Agazzi A, Ferrucci PF, Cocorocchio E, Goldhirsch A, Martinelli G. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol 106: 504-509, 1999

158. Cote RJ, Peterson HF, Chaiwun B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Gusterson B, Neville AM, for the International Breast Cancer Study Group. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. Lancet 354: 896-900, 1999

159. Nolè F, Minchella I, Colleoni M, Orvieto E, Munzone E, de Braud F, Peruzzotti G, Martinelli G, Zampino MG, Catania C, Pizzamiglio M, Veronesi P, Zurrida S, Galimberti V, Goldhirsch A, Veronesi U. Primary chemotherapy in operable breast cancer with favorable prognostic factors:

12

a pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid. Ann Oncol 10: 993-96, 1999

160. Bernhard J, Thürlimann B, Schmitz S, Castiglione-Gertsch M, Cavalli F, Morant R, Fey MF, Bonnefoi H, Goldhirsch A, Hürny C. Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: Does quality of life matter? J Clin Oncol 17: 1672-79, 1999

161. Bredart A, Didier F, Robertson C, Scaffidi E, Fonzo D, Costa A, Goldhirsch A, Autier P. Psychological distress in cancer patients attending the European Institute of Oncology in Milan. Oncology 57: 297-302, 1999

162. Colleoni M, Bonetti M, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, Rudenstam C.-M, Lindtner J, Collins J, Thürlimann B, Holmberg S, Veronesi A, Marini G, Goldhirsch A, for the International Breast Cancer Study Group. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. J Clin Oncol 18: 584-90, 2000

163. Graffeo R, Pagani O, Crivelli M, Zappa F, Borella P, Reiner M, Goldhirsch A. Parathyroid hormone-related protein in metastatic breast cancer induced hypercalcemia: A case report. Ann Oncol 11: 97-100, 2000

164. Crivellari D, Bonetti M, Castiglione-Gertsch M, Gelber RD, Rudenstam C.-M, Thürlimann B, Price KN, Coates AS, Hürny C, Bernhard J, Lindtner J, Collins J, Senn HJ, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, and Goldhirsch A, for the International Breast Cancer Study Group. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII. J Clin Oncol 18: 1412-22, 2000.

165. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Herrmann R, Honegger H, Cavalli F, Alberto P, Castiglione M, Goldhirsch A, on behalf of the Swiss Group for Clinical Cancer Research (SAKK). Docetaxel (Taxotere®) – cisplatin (TC): An effective drug combination in gastric carcinoma. Ann Oncol 11: 301-306, 2000.

166. Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thürlimann B, Rudenstam C.-M, Lindtner J, Crivellari D, Cortes-Funes H, Simoncini E, Werner ID, Coates AS, Goldhirsch A, for the International Breast Cancer Study Group (IBCSG). Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 355: 1869–74, 2000

167. Sabbioni ME, Siegrist HP, Bacchi M, Bernhard J, Castiglione M, Thurlimann B, Bonnefoi H, Perey L, Herrmann R, Goldhirsch A, Hürny C. Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment. Breast Cancer Res Treat 59: 279-87, 2000.

168. Ferretti G, Curigliano G, Pastorino U, Cittadini A, Flamini G, Calabro MG, De Pas T, Orlando L, Mandala M, Colleoni M, Spaggiari L, Granone PL, Pagliari G, de Braud F, Fazio N, Goldhirsch A. Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer. Clin Cancer Res 6: 2393-400, 2000.

169. Pagani O, Sessa C, Nolè F, Crivellari D, Lombardi D, Thürlimann B, Hess D, Borner M, Bauer J, Martinelli G, Graffeo R, Zucchetti M, D‘Incalci M, Goldhirsch A. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: A multicentric phase I–II study. Ann Oncol 11: 985-91, 2000

170. De Pas T, de Braud F, Danesi R, Sessa C, Catania C, Curigliano G, Fogli S, del Tacca M, Zampino G, Sbanotto A, Rocca A, Cinieri S, Marrocco E, Milani A, Goldhirsch A. Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naive patients with advanced non-small-cell lung cancer. Ann Oncol 11: 821-27, 2000

13

171. Colleoni M, Minchella I, Mazzarol G, Nole F, Peruzzotti G, Rocca A, Viale G, Orlando L, Ferretti G, Curigliano G, Veronesi P, Intra M, Goldhirsch A. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol 11: 1057-59, 2000

172. Colleoni M, Mandala M, Peruzzotti G, Robertson C, Bredart A, Goldhirsch A. Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet 356: 1326-27, 2000

173. Coates AS, Hurny C, Peterson HF, Bernhard J, Castiglione-Gertsch M, Gelber RD, Goldhirsch A. Quality-of-life scores predict outcome in metastatic but not early breast cancer. J Clin Oncol 18: 3768-74, 2000

174. Colleoni M, O'Neill A, Goldhirsch A, Gelber RD, Bonetti M, Thurlimann B, Price KN, Castiglione-Gertsch M, Coates AS, Lindtner J, Collins J, Senn HJ, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Rudenstam CM. Identifying Breast Cancer Patients at High Risk for Bone Metastases. J Clin Oncol. 18: 3925-35, 2000

175. Kitchen PR, Smith HJ, Henderson MA, Goldhirsch A, Castiglione-Gertsch M, Coates AS, Gusterson B, Brown RW, Gelber RD, Collins JP. Tubular carcinoma of the breast: Prognosis and response to adjuvant systemic therapy. Aust N Z J Surg 71: 27-31, 2001

176. De Pas T, de Braud F, Mandala` M, Curigliano G, Catania C, Ferretti G, Sozzi P, Solli P, Goldhirsch A. Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine. Lung Cancer 31: 267-70, 2001

177. Nole` F, Munzone E, Mandala M, Catania C, Orlando L, Zampino MG, Minchella I, Colleoni M, Peruzzotti G, Marrocco E, Goldhirsch A. Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: a phase II study. Ann Oncol 12: 95-100, 2001

178. Gelber S, Coates AS, Goldhirsch A, Castiglione-Gertsch M, Marini GL, Lindtner J, Edelmann DZ, Gudgeon A, Harvey V, and Gelber RD. Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J Clin Oncol 19: 1671-75, 2001

179. Crivellari D, Pagani O, Veronesi A, Lombardi D, Nolè F, Thürlimann B, Hess D, Corner M, Bauer J, Martinelli G, Graffeo R, Sessa C, Goldhirsch A. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 12: 353-56, 2001

180. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood. 97: 3658-61, 2001

181. Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A. Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet 358: 277-86, 2001

182. International Breast Cancer Study Group (writing Committee: B. Thurlimann, KN. Price, M. Castiglione-Gertsch, AS. Coates, A. Goldhirsch, RD. Gelber, J. Forbes, S. Holmberg, A. Veronesi, J. Bernhard, D. Zahrieh). Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node-positive breast cancer? First results of International Breast Cancer Study Group Trial 11-93. Breast 10 (Suppl 3), 130-38, 2001

183. Biffi R, de Braud F, Orsi F, Pozzi S, Arnaldi P, Goldhirsch A, Rotmensz N, Robertson C, Bellomi M, Andreoni B. A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patients. Cancer 92: 1204-12, 2001

14

184. Colleoni M, Gelber S, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, Rudenstam CM, Lindtner J, Collins J, Thurlimann B, Holmberg SB, Cortes-Funes H, Simoncini E, Murray E, Fey M, Goldhirsch A. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. J Clin Oncol 19: 4141-49, 2001

185. Curigliano G, Ferretti G, Flamini G, Goldhirsch A, de Braud F, Calabro MG, Mandaly M, Nolè F, De Pas T, D'Addessi A, Cittadini A. Diagnosis of T1 bladder transitional cell carcinoma by denaturing gradient gel electrophoresis urinalysis. Anticancer Res 21: 3015-20, 2001

186. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Clin Oncol 19: 3817-27, 2001

187. Goldhirsch A, Gelber RD, Yothers G, Gray RJ, Green S, Bryant J, Gelber S, Castiglione-Gertsch M, Coates AS. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr 30: 44-51, 2001

188. Orlando L, Colleoni M, Curigliano G, Nole F, Ferretti G, Masci G, Peruzzotti G, Minchella I, Intra M, Veronesi P, Viale G, Goldhirsch A. Chemotherapy with vinorelbine, cisplatin and continuous infusion of 5-fluorouracil in locally advanced breast cancer: a promising low-toxic regimen. Anticancer Res 21: 4135-39, 2001

189. Colleoni M, Rocca A, Sandri MT, ZorzinoL, Masci G, Nolè F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, de Braud F, Viale G, Goldhirsch A. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 13: 73-80, 2002

190. Colleoni M, Rotmensz N, Robertson C, Orlando L, Viale G, Renne G, Luini A, Veronesi P, Intra M, Orecchia R, Catalano G, Galimberti V, Nolé F, Martinelli G, Goldhirsch A. Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 13: 273-79, 2002

191. Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, Herrmann R, Pest. alozzi BC, Saletti P, Hanselmann S, Muller S, Brauchli P, Castiglione-Gertsch M, Goldhirsch A, Roth AD. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol. 20: 1759-66. 2002

192. Colleoni M, Litman HJ, Castiglione-Gertsch M, Sauerbrei W, Gelber RD, Bonetti M, Coates AS, Schumacher M, Bastert G, Rudenstam J-M, Schmoor C, Lindtner J, Collins J, Thürlimann B, Holmberg SB, Crivellari D, Beyerle C, Neumann RLA, Goldhirsch A, for the International Breast Cancer Study Group and the German Breast Cancer Study Group. Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. Br J Cancer 86: 1705-14, 2002

193. Curigliano G, Colleoni M, Renne G, Mazzarol G, Gennari R, Peruzzotti G, de Braud E, Robertson C, Maiorano E, Veronesi P, Nole F, Mandala M, Ferretti G, Viale G, Goldhirsch A. Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay. Ann Oncol: 13: 895-902, 2002

194. International Breast Cancer Study Group (IBCSG) (Writing Committee: M. Castiglione-Gertsch, KN. Price, A. Goldhirsch, AS. Coates, M. Colleoni, ML Nasi, J. Bernhard, D. Zahrieh, M. Bonetti, RD. Gelber). Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst; 94: 1054–65, 2002

195. Orlando L, Curigliano G, Colleoni M, Fazio N, Nole F, Martinelli G, Cinieri S, Graffeo R, Peruzzotti G, Goldhirsch A. Intrathecal chemotherapy in carcinomatous meningitis from breast cancer. Anticancer Res 22: 3057-59, 2002

196. Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, Coates AS, Collins J, Castiglione-Gertsch M, Gusterson BA. Ki-67 expression in breast carcinoma. Cancer 97: 1321-31, 2003

15

197. Spataro VJ, Litman H, Viale G, Maffini F, Masullo M, Golouh R, Martinez-Tello FJ, Grigolato P, Shilkin KB, Gusterson BA, Castiglione-Gertsch M, Price K, Lindtner J, Cortes-Funes H, Simoncini E, Byrne MJ, Collins J, Gelber RD, Coates AS, Goldhirsch A. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status. Cancer 97: 1591-600, 2003

198. Wallgren A, Bonetti M, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Thurlimann B, Fey M, Werner ID, Forbes JF, Price K, Coates AS, Collins J. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I Through VII. J Clin Oncol 21: 1205-13, 2003

199. Decensi A, Robertson C, Viale G, Pigatto F, Johansson H, Kisanga ER, Veronesi P, Torrisi R, Cazzaniga M, Mora S, Sandri MT, Pelosi G, Luini A, Goldhirsch A, Lien EA, Veronesi U. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 95: 779-90, 2003

200. Roila F, Ballatori E, Patoia L, Palazzo S, Veronesi A, Frassoldati A, Cetto G, Cinieri S, Goldhirsch A. Adjuvant systemic therapies in women with breast cancer: an audit of clinical practice in Italy. Ann Oncol 14: 843-48, 2003

201. Waeber M, Castiglione-Gertsch M, Dietrich D, Thürlimann B, Goldhirsch A, Brunner KW, Borner MM. On behalf of the Swiss Group for Clinical Cancer Research (SAKK). Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. Ann Oncol 14: 1215-21, 2003

202. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21: 3357-65, 2003

203. Colleoni M, Curigliano G, Minchella I, Peruzzotti G, Nolè F, Mazzarol G, Renne G, Orlando L, Rocca A, Veronesi P, Intra M, Viale G, Sandri MT, Severi G & Goldhirsch A. Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase. Ann Oncol 14: 1477-83, 2003

204. Crivellari D, Price K, Gelber RD, Castiglione-Gertsch M, Rudenstam C-M, Lindtner J, Fey MF, Senn H-J, Coates AS, Collins J, and Goldhirsch A. Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-Year results of International Breast Cancer Study Group Trial IV. J Clin Oncol, 21: 4517-23, 2003

205. Castiglione-Gertsch M, O’Neill A, Price KN, Goldhirsch A, Coates AS, Colleoni M, Nasi ML, Bonetti M, Gelber RD; International Breast Cancer Study Group. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 95: 1833-46, 2003

206. Biganzoli L, Goldhirsch A, Straehle C, Castiglione-Gertsch M, Therasse P, Aapro M, Minisini A, Piccart MJ on behalf of BIG. Adjuvant chemotherapy in elderly patients with breast cancer: a survey of the Breast International Group (BIG). Ann Oncol 15: 207-10, 2004

207. Mandalà M, Curigliano G, Bucciarelli P, Ferretti G, Mannucci PM, Colleoni M, Ventura A, Peruzzotti G, Severi G, Pelicci PG, Biffi R, Orsi F, Cinieri S, Goldhirsch A. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and central venous catheter. Ann Oncol 15: 590-93, 2004

208. Laszlo D, Agazzi A, Goldhirsch A, Cinieri S, Bertolini F, Rabascio C, Pruneri G, Calabrese L, Cocquio A, Martinelli G. Tailored therapy of adult acute leukaemia in Jehovah’s Witnesses: unjustified reluctance to treat. Eur J Haematol 72: 264-267, 2004

16

209. Roth AD, Maibach R, Fazio N, Sessa C, Stupp R, Morant R, Herrmann R, Borner MM, Goldhirsch A, de Braud F. On behalf of the Swiss Group for Clinical Cancer Research (SAKK). 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere®)-cisplatin in advanced gastric carcinoma: a phase I-II trial. Ann Oncol 15: 759-64, 2004

210. Thürlimann B, Hess D, Koberle D, Senn I, Ballabeni P, Pagani O, Perey L, Aebi S, Rochlitz C, Goldhirsch A. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) Trial. Breast Cancer Res Treat 85: 247-54, 2004

211. Berclaz G, Li S, Price KN, Coates AS, Castiglione-Gertsch M, Rudenstam CM, Holmberg SB, Lindtner J, Erien D, Collins J, Snyder R, Thurlimann B, Fey MF, Mendiola C, Werner ID, Simoncini E, Crivellari D, Gelber RD, Goldhirsch A; International Breast Cancer Study Group. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol 15: 875-84, 2004

212. Rabascio C, Muratori E, Moncuso P, Calleri A, Raia V, Foutz T, Cinieri S, Veronesi G, Pruneri G, Lampertico P, Iavarone M, Martinelli G, Goldhirsch A, Bertolini F. Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Cancer Res 64: 4373-77, 2004

213. Curigliano G, Rigo R, Colleoni M, Braud FD, Nole F, Formica V, Orlando L, Cinieri S, Torrisi R, Cardillo A, Peruzzotti G, Medici M, Ardito R, Minchella I, Goldhirsch A. Adjuvant therapy for very young women with breast cancer: response according to biologic and endocrine features. Clin Breast Cancer: 5: 125-30, 2004

214. Intra M, Rotmensz N, Viale G, Mariani L, Bonanni B, Mastropasqua MG, Galimberti V, Gennari R, Veronesi P, Colleoni M, Tousimis E, Galli A, Goldhirsch A, Veronesi U. Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution. Division of Breast Surgery, European Institute of Oncology, Milan, Italy. Cancer. 101: 905-12, 2004

215. Gennari R, Curigliano G, Rotmensz N, Robertson C, Colleoni M, Zurrida S, Nole F, de Braud F, Orlando L, Leonardi MC, Galimberti V, Intra M, Veronesi P, Renne G, Cinieri S, Audisio RA, Luini A, Orecchia R, Viale G, Goldhirsch A. Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients. Cancer 101: 1302-10, 2004

216. Sabbioni ME, Bernhard J, Siegrist HP, Schmitz SF, Castiglione-Gertsch M, Thürlimann B, Bonnefoi H, Perey L, Herrmann R, Goldhirsch A, Hürny C. Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy? Breast Cancer Res Treat 87: 75-86, 2004

217. Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, Gelber RD, Curigliano G, Torrisi R, Luini A, Intra M, Galimberti V, Renne G, Nole F, Peruzzotti G, Goldhirsch A. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 10:6622-28, 2004

218. Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Viale G, Renne G, Casadio C, Veronesi P, Intra M, Torrisi R, and Goldhirsch A. Minimal and small size invasive bresat cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies. Ann Oncol 15: 1633-39, 2004

219. International Breast Cancer Study Group (Writing Committee: Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price K, Zahrieh D, Gelber R, Coates A, Goldhirsch A). Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol 15: 1749-59, 2004

17

220. Hess D, Thürlimann B, Pagani O, Aebi S, Rauch D, Ballabeni P, Rufener B, Castiglione-Gertsch M & Goldhirsch A. On behalf of the Swiss Group of Clinical Cancer Research (SAKK). Capecitabine and vinorelbine in elderly patients (≥65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). Ann Oncol 15: 1760-1765, 2004

221. Colleoni M, Zahrieh D, Gelber RD, Holmberg SB, Mattsson JE, Rudenstam CM, Lindtner J, Erzen D, Snyder R, Collins J, Fey MF, Thurlimann B, Crivellari D, Murray E, Mendiola C. Pagani O, Castiglione-Gertsch M, Coates AS, Price K, Goldhirsch A. Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience. J Clin Oncol 23: 1390-1400, 2005

222. Colleoni M, Rotmensz N, Perruzzotti G, Maisonneuve P, Mazzarol G, Pruneri G, Luini A, Intra M, Veronesi P, Galimberti V, Torrisi R, Cardillo A, Goldhirsch A, Viale G. Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. J Clin Oncol 23: 1379-1389, 2005

223. Gentilini O, Masullo M, Rotmensz N, Peccatori F, Mazzarol G, Smeets A, Simsek S, De Dosso S. Veronesi P, Intra M, Zurrida S, Viale G, Goldhirsch A, Veronesi U. Breast cancer diagnosed during pregnancy and lactation: biological features and treatment options. Eur J Surg Oncol 31: 232-236, 2005

224. Colleoni M, Li S, Gelber RD, Coates AS, Castiglione-Gertsch M, Price KN, Lindtner J, Rudenstam C-M, Crivellari D, Collins D, Collins J, Pagani O, Simoncini E, Thürlimann B, Murray E, Forbes J, Eržen D, Holmberg S, Veronesi A & Goldhirsch A On behalf of the International Breast Cancer Study Group (IBCSG). Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. Ann Oncol 16: 716-725, 2005

225. Orlando L, Renne G, Rocca A, Curigliano G, Colleoni M, Severi G, Peruzzotti G, Cinieri S, Viale G, Sanna G & Goldhirsch A. Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype. Ann Oncol 16: 1094-1099, 2005

226. Pagani O, Sessa C, Nolè F, Munzone E, Crivellari D, Lombardi D, Thürlimann B, Hess D, Graffeo R, Ruggeri M, Longhi S & Goldhirsch A. Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer. Ann Oncol 16: 1609-1617, 2005

227. Catania C, Didier F, Leon ME, Sbanotto A, Mariani L, Nole F, Leida E, Rocca A, Pas TD, Goldhirsch A. Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possibile prejudices of patients with cancer. Breast Cancer Res Treat 92: 265-272, 2005

228. Gruber G, Bonetti M, Nasi ML, Price KN, Castiglione-Gertsch M, Rudenstam CM, Holmberg SB, Lindtner J, Golouh R, Collins J, Crivellari D, Carbone A, Thurlimann B, Simoncini E, Fey MF, Gelber RD, Coates AS, Goldhirsch A. Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group trial VI. J Clin Oncol. 23:7089-97, 2005

229. Curigliano G, Petit JY, Bertolini F, Colleoni M, Peruzzotti G, de Braud F, Gandini S, Giraldo A, Martella S, Orlando L, Munzone E, Pietri E, Luini A, Goldhirsch A. Systemic Effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or extended surgery. Breast Cancer Res Treat. 93: 35-40, 2005

230. Munzone E, Nolè F, Sanna G, Goldhirsch A. Response of bilateral choroidal metastases of breast cancer to therapy with trastuzumab. Breast 14: 380-383, 2005

18

231. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang C-S, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Sǔtő, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, and Gelber RD, for the Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659-1672, 2005

232. Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardly A, Price KN, Goldhirsch A; Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353: 2747-2757, 2005

233. Curigliano G, Mandalà M, Sbanotto A, Ferretti G, Bucciarelli P, Peruzzotti G, de Braud F, De Pas T, Spitaleri G, Pietri E, Orsi F, Banfi MG, Goldhirsch A. Factor v leiden mutation in patients with breast cancer with a central venous catheter: risk of deep vein thrombosis. Supp Cancer Ther 3: 98-102, 2006

234. Nolè F, Catania C, Sanna G, Imadalou K, Munzone E, Adamoli L, Longerey B, Blanchot G & Goldhirsch A. Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. Ann Oncol 17: 322-329, 2006

235. Gianni L, Panzini I, Li S, Gelber RD, Collins J, Holmberg SB, Crivellari D, Castiglione-Gertsch M, Goldhirsch A, Coates AS, Ravaioli A. Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer. Cancer 106: 505-513, 2006

236. Munzone E, Curigliano G, Rocca A, Bonizzi G, Renne G, Goldhirsch A and Nolé F. Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Res 8: R4, 2006

237. Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G, Ghisini R, Sandri MT, Zorzino L, Nolè F, Viale G & Goldhirsch A. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 17: 232-238, 2006

238. Basser RL, O’Neill A, Martinelli G, Green MD, Peccatori F, Cinieri S, Coates AS, Gelber RD, Aebi S, Castiglione-Gertsch M, Viale G, Price KN, Goldhirsch A. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group trial 15-95. J Clin Oncol 24: 370-378, 2006

239. Rudenstam C-M, Zahrieh D, Forbes JF, Crivellari D, Holmberg SB, Rey P, Dent D, Campbell I, Bernhard J, Price KN, Castiglione-Gertsch M, Goldhirsch A, Gelber RD, Coates AS. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group trial 10-93. J Clin Oncol 24: 337-344, 2006

240. Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, Pruneri G, Agliano A, Goldhirsch A, Shaked Y, Kerbel RS, Bertolini F. Circulating endothelial cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006 Mar 16; [Epub ahead of print]

241. Nole F, Catania C, Munzone E, Rocca A, Verri E, Sanna G, Ascione G, Adamoli L, Zampino MG, Minchella I, Goldhirsch A. Capecitabine/Vinorelbine: an effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer. Clin Breast Cancer 6: 518-524, 2006

242. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, Blohmer J-U, Eiermann W, Jackesz R, Jonat W, Lebeau A, Loibl S, Miller W, Seeber S, Semiglazov V, Smith R, Souchon R, Stearns V, Untch M, and von Minckwitz G. Recommendations from an

19

international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24: 1940-1949, 2006

243. Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS & Goldhirsch A. For the International Breast Cancer Study Group. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 17: 935-944, 2006

244. Zampino MG, Verri E, Locatelli M, Curigliano G, Ascione G, Sbanotto A, Rocca A, Verweij F, Matei V, Scardino E, Decobelli O, Goldhirsch A, Nole F. Vinorelbine-based chemotherapy in hormone-refractory prostate cancer. Anticancer Res 26: 2375-2380, 2006

245. Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Orlando L, Ghisini R, Viale G, Pruneti G, Veronesi P, Luini A, Intra M, Cardillo A, Torrisi R, Rocca A & Goldhirsch A. Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann Oncol 17: 1497-1503, 2006

246. Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD; International Breast Cancer Study Group. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol 24: 1332-1341, 2006

247. Orlando L, Cardillo A, Rocca A, Balduzzi A, Ghisini R, Peruzzotti G, Goldhirsch A, D’Alessandro C, Cinieri S, Preda L, Colleoni M. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs 17: 961-967, 2006

248. Sanna G, Preda L, Bruschini R, Rocca MC, Ferretti S, Adamoli L, Verri E, Franceschelli L, Goldhirsch A, Nolé F. Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer. Ann Oncol 17: 1512-1516, 2006

249. Gentilini O, Intra M, Gandini S, Peruzzotti G, Winnikow E, Luini A, Veronesi P, Galimberti V, Goldhirsch A, and Veronesi U. Ipsilateral breast tumor reappearance in patients treated with conservative surgery after primary chemotherapy. The role of surgical margins on outcome. J Surg Oncol 94: 375-379, 2006

250. Regan MM, Viale G, Mastropasqua MG, Maiorano E, Golouh R, Carbone A, Brown B, Suurkula M, Langman G, Mazzucchelli L, Braye S, Grigolato P, Gelber RD, Castiglione-Gertsch M, Price KN, Coates AS, Goldhirsch A, Gusterson B; International Breast Cancer Study Group. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst 98: 1571-1581, 2006

251. Rocca A, Peruzzotti G, Ghisini R, Viale G, Veronesi P, Luini A, Intra M, Pietri E, Curigliano G, Giovanardi F, Maisonneuve P, Goldhirsch A, Colleoni M. A randomized phase II trial comparino preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer. Anticancer Drugs 17: 1201-1209, 2006

252. Torrisi R, Orlando L, Ghisini R, Veronesi P, Intra M, Rocca A, Balduzzi A, Cardillo A, Goldhirsch A and Colleoni M. A phase II study of primary dose-dense sequential doxorubicin plus cyclophosphamide and docetaxel in cT4 breast cancer. Anticancer Res 26: 3861-3864, 2006

253. Perey L, Paridaens R, Hawle H, Zaman K, Nolé F, Wildiers H, Fiche M, Dietrich D, Clément P, Köberle D, Goldhirsch A & Thürlimann B. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol 18: 64-69, 2007

254. Catania C, De Pas TM, Pelosi G, Manzotti M, Adamoli L, Nolé F, Goldhirsch A. Erlotinib-induced breast cancer regression. Ann Pharmacother 40: 2043-2047, 2006

20

255. Orlando L, Cardillo A, Ghisini R, Rocca A, Balduzzi A, Torrisi R, Peruzzotti G, Goldhirsch A, Pietri E, Colleoni M. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 6: 225, 2006 Sept 15 [Indexed for MEDLINE]

256. Bernhard J, Zahrieh D, Castiglione-Gertsch M, Hürny C, Gelber RD, Forbes JF, Murray E, Collins J, Aebi S, Thürlimann B, Price KN, Goldhirsch A, and Coates AS. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients - the International Breast Cancer Study Group Trial VIII. J Clin Oncol 25: 263-270, 2007

257. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sánchez Rovira P, Piccart-Gebhart MJ, for the HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369: 29-36, 2007

258. Sanna G, Lorizzo K, Rotmensz N, Bagnardi V, Cinieri S, Colleoni M, Nolé F, Goldhirsch A. Breast cancer in Hodgkin’s disease and non-Hodgkin’s lymphoma survivors. Ann Oncol 18: 288-292, 2007

259. Gentilini O, Botteri E, Rotmensz N, Santillo B, Peradze N, Saihum RC, Intra M, Luini A, Galimberti V, Goldhirsch A & Veronesi U. When can a second conservative approach be considered for ipsilateral breast tumour recurrence? Ann Oncol 18: 468-472, 2007

260. Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret J-M, Pienkowski T, Wardley A, Jakobsen EH, Price KN, and Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25: 486-492, 2007

261. Torrisi R, Colleoni M, Veronesi P, Rocca A, Peruzzotti G, Severi G, Medici M, Renne G, Intra M, Luini A, Nole F, Viale G, Goldhirsch A. Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancer. Breast 16: 73-80, 2007

262. Catania C, Ascione G, Adamoli L, De Pas T, Medici M, Franceschelli L, Verri E, Magni E, Sanna G, Torrisi R, Goldhirsch A, Nole F. Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre. Breast Cancer Res Treat 106: 97-103, 2007

263. Keshaviah A, Dellapasqua S, Rotmensz N, Lindtner J, Crivellari D, Collins J, Colleoni M, Thürlimann B, Mendiola C, Aebi S, Price K, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber R, Coates A, Goldhirsch A. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Ann Oncol 18: 701-708, 2007

264. Veronesi G, Scanagatta P, Goldhirsch A, Rietjens M, Colleoni M, Pelosi G, Spaggiari L. Results of chest wall resection for recurrent or locally advanced breast malignancies. Breast 16: 297-302, 2007

265. Mauriac L, Keshaviah A, Debled M, Mouridsen H, Forbes J, Thürlimann B, Paridaens R, Monnier A, Lang I, Wardley A, Nogaret JM, Gelber RD, Castiglione-Gertsch M, Price K, Coates A, Smith I, Viale G, Rabaglio M, Zabaznyi N, Goldhirsch A. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 18: 859-867, 2007

266. Piccart M, Goldhirsch A, Wood W, Pritchard K, Baselga J, Reaby L, Kossler I, Kyriakides S, Norton L, Coates A. Keeping faith with trial volunteers. Nature 446: 137-138, 2007

21

267. Colleoni M, Gelber S, Simoncini E, Pagani O, Gelber RD, Price KN, Castiglione-Gertsch M, Coates AS, and Goldhirsch A, on behalf of the International Breast Cancer Study Group. Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93. Ann Oncol 18: 1177-1184, 2007

268. Karlsson P, Cole BF, Price KN, Coates AS, Castiglione-Gertsch M, Gusterson BA, Murray E, Lindtner J, Collins JP, Holmberg SB, Fey MF, Thürlimann B, Crivellari D, Forbes JF, Gelber RD, Goldhirsch A, and Wallgren A. The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. J Clin Oncol 25: 2019-2026, 2007

269. Partridge A, Gelber S, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Winer E. Age of menopause among women who remain premenopausal following treatment for early breast cancer: Long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer 43: 1646-1653, 2007

270. Curigliano G, Balduzzi A, Cardillo A, Ghisini R, Peruzzotti G, Orlando L, Torrisi R, Dellapasqua S, Lunghi L, Goldhirsch A, Colleoni M. Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter. Support Care Cancer 15: 1213-1217, 2007

271. Saletti P, Berthold D, Ghielmini M, Zucca E, Fazio N, Goldhirsch A, Cavalli F. Adjuvant chemotherapy (ECF regimen) for patients with gastric adenocarcinoma. Hepatogastroenterology 54: 969-972, 2007

272. Curigliano G, Goldhirsch A. To switch or not to switch: implications of sequencing adjuvant endocrine therapy in patients with breast cancer. Nat Clin Pract Oncol 4: 510-511, 2007

273. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn H-J & Panel Members. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18: 1133-1144, 2007

274. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell’Orto P, Bruun Rasmussen B, Raffoul J, Neven P, Orosz Z, Braye S, Öhlschlegel C, Thürlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, and Coates AS. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal women with early breast cancer: results from the BIG 1-98 collaborative groups. J Clin Oncol 25: 3846-3852, 2007

275. Curigliano G, Rescigno M, Goldhirsch A. Immunology and breast cancer: Therapeutic cancer vaccines. Breast 16 (Suppl 2): 20-26, 2007

276. Sanna G, Franceschelli L, Rotmensz N, Botteri E, Adamoli L, Marenghi C, Munzone E, Cossu Rocca M, Verri E, Minchella I, Medici M, Catania C, Mangi E, Goldhirsch A, Nolè F. Brain metastases in patients with advanced breast cancer. Anticancer Res 27: 2865-2869, 2007

277. Dellapasqua S, Colleoni M, Castiglione M, Goldhirsch A. New criteria for selecting elderly patients for breast cancer adjuvant treatment studies. Oncologist 12: 952-959, 2007

278. Colleoni M, Rotmensz N, Maisonneuve P, Sonzogni A, Pruneri G, Casadio C, Luini A, Veronesi P, Intra M, Galimberti V, Torrisi R, Andrighetto S, Ghisini R, Goldhirsch A, Viale G. Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. Ann Oncol 18: 1632-1640, 2007

279. Torrisi R, Bagnardi V, Pruneri G, Ghisini R, Bottiglieri L, Magni E, Veronesi P, D’Alessandro C, Luini A, Dellapasqua S, Viale G, Goldhirsch A, Colleoni M. Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. Br J Cancer 97: 802-808, 2007

22

280. Catania C, Medici M, Magni E, Munzone E, Cardinale D, Adamoli L, Sanna G, Minchella I, Radice D, Goldhirsch A & Nolè F. Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination. Ann Oncol 18: 1969-1975, 2007

281. Torrisi R, Rotmensz N, Bagnardi V, Viale G, Curto BD, Dell’Orto P, Veronesi P, Luini A, D’Alessandro C, Cardillo A, Goldhirsch A, Colleoni M. HER2 status in early breast cancer: Relevance of cell staining patterns, gene amplification and polysomy 17. Eur J Cancer 43: 2339-2344, 2007

282. Meglio GD, Fazio N, Nolè F, Della Vigna P, Lorizzo K, Goldhirsch A, Farris A. Successful treatment with low-dose oral chemotherapy in a patient with metastatic hepatocellular carcinoma. Acta Oncol 46: 1205-1206, 2007

283. Mouridsen H, Keshaviah A, Coates AS, Rabaglio M, Castiglione-Gertsch M, Sun Z, Thürlimann B, Mauriac L, Forbes JF, Paridaens R, Gelber RD, Colleoni M, Smith I, Price KN, Goldhirsch A. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol 25: 5715-5722, 2007

284. Dowsett M, Goldhirsch A, Hayes DF, Senn HJ, Wood W, Viale G. International web-based consultation on priorities for translational breast cancer research. Breast Cancer Res 9: R81, 2007

285. Francis P, Crown J, Di Leo A, Buyse M, Balil A, Andersson M, Nordenskjöld B, Lang I, Jakesz R, Vorobiof D, Gutiérrez J, van Hazel G, Dolci S, Jamin S, Bendahmane B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Piccart-Gebhart M; on behalf of the BIG 02-98 Collaborative Group. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst 100: 121-133, 2008

286. Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell’Orto P, Del Curto B, Henriksen KL, Mastropqaqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G; for the BIG 1-98 Collaborative and International Breast Cancer Study Groups. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 9: 23-28, 2008

287. Gianni L, Cole BF, Panzini I, Snyder R, Holmberg SB, Byrne M, Crivellari D, Colleoni MA, Aebi S, Simoncini E, Pagani O, Castiglione-Gertsch M, Price KN, Goldhirsch A, Coates AS, Ravaioli A. Anemia during adjuvant non-taxane chemotherapy for early breast cancer: incidence and risk factors from two trials of the International Breast Cancer Study Group. Support Care Cancer 16: 67-74, 2008

288. Bernhard J, Zahrieh D, Zhang, JJ, Martinelli G, Basser R, Hürny C, Forbes JF, Aebi S, Yeo W, Thürlimann B, Green MD, Colleoni M, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Coates AS. Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. Br J Cancer 98: 25-33, 2008

289. Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, Price KN, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Gusterson BA, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Coates AS; on behalf of the International Breast Cancer Study Group. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 100: 207-212, 2008

290. Rocca A, Viale G, Gelber RD, Bottiglieri L, Gelber S, Pruneri G, Ghisini R, Balduzzi A, Pietri E, D’Alessandro C, Goldhirsch A, Colleoni M. Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression. Cancer Chemother Pharmacol 61: 965-971, 2008

23

291. Colleoni M, Viale G, Zahrieh D, Bottiglieri L, Gelber RD, Veronesi P, Balduzzi A, Torrisi R, Luini A, Intra M, Dellapasqua S, Cardillo A, Ghisini R, Peruzzotti G & Goldhirsch A. Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Ann Oncol 19: 465-472, 2008

292. Ravaioli A, Monti F, Regan MM, Maffini F, Mastropasqua MG, Spataro V, Castiglione-Gertsch M, Panzini I, Gianni L, Goldhirsch A, Coates A, Price KN, Gusterson BA, Viale G; on behalf of the International Breast Cancer Study Group. p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. Ann Oncol 19: 660-668, 2008

293. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovàcs A, Pillay K, Öhlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, and Coates AS. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors – International Breast Cancer Study Group. J Clin Oncol 26: 1404-1410, 2008

294. Nolé F, Munzone E, Zorzino L, Minchella I, Salvatici M, Botteri E, Medici M, Verri E, Adamoli L, Rotmensz N, Goldhirsch A, Sandri MT. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol 19: 891-897, 2008

295. Montagna E, Bagnardi V, Rotmensz N, Rodriguez J, Veronesi P, Luini A, Intra M, Scarano E, Cardillo A, Torrisi R, Viale G, Goldhirsch A, Colleoni M. Factors that predict early treatment failure for patients with locally advanced (T4) breast cancer. Br J Cancer 98: 1745-1752, 2008

296. Biffi R, Orsi F, Zampino MG, Chiappa A, Fazio N, De Braud F, Bonomo G, Monfardini L, Della Vigna P, Luca F, Bodei L, Bartolomei M, Catalano G, Leonardi MC, Ferrari ME, Andreoni B, Goldhirsch A, Paganelli G, Orecchia R. Institutional guidelines and ongoing studies in management of liver tumours: the experience of the European Institute of Oncology, ecancermedicalscience 1: 64; 2008

297. Untch M, Gelber RD, Jackisch C, Procter M, Baselga J, Bell R, Cameron D, Bari M, Smith I, Leyland-Jones B, de Azambuja E, Wermuth P, Khasanov R, Feng-Yi F, Constantin C, Mayordomo JI, Su CH, Yu SY, Lluch A, Senkus-Konefka E, Price C, Haslbauer F, Sahui TS, Srimuninnimit V, Colleoni M, Coates AS, Piccart-Gebhart MJ, Goldhirsch A; for the HERA Study Team. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 19: 1090-1096, 2008

298. Crivellari D, Sun Z, Coates AS, Price KN, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens RJ, Castiglione-Gertsch M, Gelber RD, Colleoni M, Làng I, Del Mastro L, Gladieff L, Rabaglio M, Smith IE, Chirgwin JH, and Goldhirsch A. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 26: 1972-1979, 2008

299. Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Goldhirsch A, Rocca A, Pietri E, Colleoni MA. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26: 4899-4905, 2008

300. Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Thürlimann B, Murray E, Viale G, Castiglione-Gertsch M, Coates AS, and Goldhirsch A. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol J Clin Oncol 26: 3006-3014, 2008

301. Regan MM, Pagani O, Walley B, Torrisi R, Perez EA, Francis P, Fleming GF, Price KN, Thürlimann B, Maibach R, Castiglione-Gertsch M, Coates AS, Goldhirsch A, Gelber RD for the SOFT/TEXT/PERCHE Steering Committee and the International Breast Cancer Study Group.

24

Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol 19: 1231-1241, 2008

302. Torrisi R, Balduzzi A, Ghisini R, Rocca A, Bottiglieri L, Giovanardi F, Veronesi P, Luini A, Orlando L, Viale G, Goldhirsch A, Colleoni M. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol 62: 667-672, 2008

303. Gruber G, Cole, BF, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Golouh R, Collins J, Crivellari D, Thürlimann B, Simoncini E, Fey MF, Gelber RD, Coates AS, Price KN, Goldhirsch A, Viale G & Gusterson BA for the International Breast Cancer Study Group. Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. Ann Oncol 19: 1393-1401, 2008

304. Catania C, De Pas T, Goldhirsch A, Radice D, Adamoli L, Medici M, Verri E, Marenghi C, de Braud F, Nolé F. Participation in clinical trials as viewed by the patient: understanding cultural and emotional aspects which influence choice. Oncology 74: 177-187, 2008

305. D’Alessandro C, Dellapasqua S, Orlando L, Santoro L, Maisonneuve P, Torrisi R, Balduzzi A, Scarano E, Ghisini R, Peruzzotti G, Goldhirsch A, Colleoni M. Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy. Breast J 14: 435-441, 2008

306. Torrisi R, Bagnardi V, Cardillo A, Bertolini F, Scarano E, Orlando L, Mancuso P, Luini A, Calleri A, Viale G, Goldhirsch A, Colleoni M. Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. Br J Cancer 99: 1564-1571, 2008

307. Orlando L, Del Curto B, Gandini S, Ghisini R, Pietri E, Torrisi R, Balduzzi A, Cardillo A, Dellapasqua S, Veronesi P, Viale G, Goldhirsch A, Colleoni M. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer. Breast 17: 506-511, 2008

308. Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell’Orto P, Maiorano E, MacGrogan G, Braye SG, Öhlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, and Goldhirsch A. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: Results from Breast International Group trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26: 5569-5575, 2008

309. Torrisi R, Dellapasqua S, Ghisini R, Viale G, Veronesi P, Luini A, Intra M, Peruzzotti G, Rocca A, Balduzzi A, Cardillo A, Goldhirsch A, Colleoni M. Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors. Breast 17: 654-660, 2008

310. Thürlimann B, Price KN, Gelber RD, Holmberg SB, Crivellari D, Colleoni M, Collins J, Forbes JF, Castiglione-Gertsch M, Coates AS, Goldhirsch A. Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Breast Cancer Res Treat 113: 137-144, 2009

311. Rocca A, Minucci S, Tosti G, Croci D, Contegno F, Ballarini M, Nolé F, Munzone E, Salmaggi A, Goldhirsch A, Pelicci PG, Testori A. A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br J Cancer 100: 28-36, 2009

312. Gianni L, Gelber S, Ravaioli A, Price KN, Panzini I, Fantini M, Castiglione-Gertsch M, Pagani O, Simoncini E, Gelber RD, Coates AS, Goldhirsch A. Second non-breast primary cancer

25

following adjuvant therapy for early breast cancer: A report from the International Breast Cancer Study Group. Eur J Cancer 45: 561-571, 2009

313. Gentilini O, Botteri E, Rotmensz N, Da Lima L, Caliskan M, Garcia-Etienne CA, Sosnovskikh I, Intra M, Mazzarol G, Musmeci S, Veronesi P, Galimberti V, Luini A, Viale G, Goldhirsch A, Veronesi U. Conservative surgery in patients with multifocal/multicentric breast cancer. Breast Cancer Res Treat 113: 577-583, 2009

314. Guerrieri-Gonzaga A, Botteri E, Rotmensz N, Bassi F, Intra M, Serrano D, Renne G, Luini A, Cazzaniga M, Goldhirsch A, Colleoni M, Viale G, Ivaldi G, Bagnardi V, Lazzeroni M, Decensi A, Veronesi U, Bonanni B. Ductal intraepithelial neoplasia: postsurgical outcome for 1,267 women cared for in one single institution over 10 years. Oncologist 14: 201-212, 2009

315. Biffi R, Orsi F, Pozzi S, Pace U, Bonomo G, Monfardini L, Della Vigna P, Rotmensz N, Radice D, Zampino MG, Fazio N, de Braud F, Andreoni B, Goldhirsch A. Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial. Ann Oncol 20: 935-940, 2009

316. Balduzzi A, Montagna E, Bagnardi V, Torrisi R, Bertolini F, Mancuso P, Scarano E, Viale G, Veronesi P, Cardillo A, Orlando L, Goldhirsch A, Colleoni M. Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features. Anticancer Drugs 20: 197-203, 2009

317. Sun Z, Goldhirsch A, Price KN, Colleoni M, Ravaioli A, Simoncini E, Campbell I, Gelber RD, Towler M. Bone quality test (BQT) scores of fingernails in postmenopausal patients treated with adjuvant letrozole or tamoxifen for early breast cancer. Breast 18: 84-88, 2009

318. Peccatori FA, Azim HA Jr, Scarfone G, Gadducci A, Bonazzi C, Gentilini O, Galimberti V, Intra M, Locatelli M, Acaia B, Rossi P, Cinieri S, Calabrese L, Goldhirsch A. Weekly epirubicin in the treatment of gestational breast cancer (GBC). Breast Cancer Res Treat 115: 591-594, 2009

319. Viale G, Rotmensz N, Maisonneuve P, Bottiglieri L, Montagna E, Luini A, Veronesi P, Intra M, Torrisi R, Cardillo A, Campagnoli E, Goldhirsch A, Colleoni M. Invasive ductal carcinoma of the breast with the «triple-negative» phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 116: 317-328, 2009

320. Colleoni M, Bagnardi V, Rotmensz N, Gelber RD, Viale G, Pruneri G, Veronesi P, Torrisi R, Cardillo A, Montagna E, Campagnoli E, Luini A, Intra M, Galimberti V, Scarano E, Peruzzotti G, Goldhirsch A. Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res Treat 116: 359-369, 2009

321. Colleoni M, Bagnardi V, Rotmensz N, Dellapasqua S, Viale G, Pruneri G, Veronesi P, Torrisi R, Luini A, Intra M, Galimberti V, Montagna E, Goldhirsch A. A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer. Ann Oncol 20: 1178-1184, 2009

322. Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price KN, Gelber RD, Holmberg SB, Crivellari D, Collins J, Lindtner J, Thürlimann B, Fey MF, Murray E, Forbes JF, Coates AS, Goldhirsch A, for the International Breast Cancer Study Group. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Res Treat 116: 491-500, 2009

323. Colleoni M, Sun Z, Martinelli G, Basser RL, Coates AS, Gelber RD, Green MD, Peccatori F, Cinieri S, Aebi S, Viale G, Price KN & Goldhirsch A; For the International Breast Cancer Study Group. The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Ann Oncol 20: 1344-1351, 2009

26

324. Nolè F, Crivellari D, Mattioli R, Pinotti G, Foa P, Verri E, Fougeray R, Brandely M, Goldhirsch A. Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol 64: 673-680, 2009

325. Pagani O, Price KN, Gelber RD, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Thürlimann B, Collins J, Fey MF, Coates AS, Goldhirsch A, International Breast Cancer Study Group (IBCSG). Patterns of recurrence of early breast cancer according to estrogen receptor status_a therapeutic target for a quarter of a century. Breast Cancer Res Treat 117: 319-324, 2009

326. The BIG 1-98 collaborative group (writing committee; Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes JF, Price KN, Regan MM, Gelber RD, Coates AS). Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 361: 766-776, 2009

327. Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thürlimann B, Mouridsen H, Campone M, Forbes JF, Paridaens RJ, Colleoni M, Pienkowski T, Nogaret J-M, Láng I, Smith I, Relber RD, Goldhirsch A & Coates AS for the BIG 1-98 Collaborative and International Breast Cancer Study Groups. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 20: 1489-1498, 2009

328. Chiappa A, Makuuchi M, Lygidakis NJ, Zbar AP, Chong G, Bertani E, Sitzler PJ, Biffi R, Pace U, Bianchi PP, Contino G, Misitano P, Orsi F, Travaini L, Trifirò G, Zampino MG, Fazio N, Goldhirsch A, Andreoni B. The management of colorectal liver metastases: expanding the role of hepatic resection in the age of multimodal therapy. Crit Rev Oncol Hematol 72: 65-75, 2009

329. Viale G, Rotmensz N, Maisonneuve P, Orvieto E, Maiorano E, Galimberti V, Luini A, Colleoni M, Goldhirsch A, Coates AS. Lack of prognostic significance of “classic” lobular breast carcinoma: a matched, single institution series. Breast Cancer Res Treat 117: 211-214, 2009

330. Andreoni B, Goldhirsch A, Orecchia R, Venturino M, Spirito R, Tadini L, Corbellini C, Bertani E, Veronesi U. Correlation between administered treatment and patient’s Living Will. ecancermedicalscience 3: 158, 2009; DOI: 10.3332/ecancer.2009.158 (online)

331. Montagna E, Viale G, Rotmensz N, Maisonneuve P, Galimberti V, Luini A, Intra M, Veronesi P, Mazzarol G, Pruneri G, Renne G, Torrisi R, Cardillo A, Cancello G, Goldhirsch A, Colleoni M. Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure. Breast Cancer Res Treat 118: 385-394, 2009

332. Curigliano G, Viale G, Bagnardi V, Fumagalli L, Locatelli M, Rotmensz N, Ghisini R, Colleoni M, Munzone E, Veronesi P, Zurrida S, Nolè F, Goldhirsch A. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 27: 5693-5699, 2009

333. Curigliano G, Locatelli M, Fumagalli L, Goldhirsch A. Immunizing against breast cancer: A new swing for an old sword. Breast 18 (Suppl 3): S51-S54, 2009

334. Colleoni M, Viale G, Goldhirsch A. Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting. Breast 18 (Suppl 3): S137-S140, 2009

335. Calleri A, Bono A, Bagnardi V, Quarna J, Mancuso P, Rabascio C, Dellapasqua S, Campagnoli E, Shaked Y, Goldhirsch A, Colleoni M, Bertolini F. Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab. Clin Cancer Res 15: 7652-7657, 2009

336. Curigliano G, Spitaleri G, Magni E, Lorizzo K, De Cobelli O, Locatelli M, Fumagalli L, Adamoli L, Cossu Rocca M, Verri E, De Pas T, Jereczek-Fossa B, Martinelli G, Goldhirsch A, Nolé F. Cisplatin, etoposide and continuous bleomycin in patients with testicular germ cell tumors: efficacy and toxicity data from a retrospective study. J Chemother 21: 687-692, 2009

27

337. Rocca A, Cancello G, Bagnardi V, Sandri MT, Torrisi R, Zorzino L, Viale G, Pietri E, Veronesi P, Dellapasqua S, Ferrucci F, Luini A, Johansson H, Ghisini R, Goldhirsch A, Colleoni M. Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer. Anticancer Res 29: 5111-5119, 2009

338. Gentilini O, Cremonesi M, Toesca A, Colombo N, Peccatori F, Sironi R, Sangalli C, Rotmensz N, Pedroli G, Viale G, Veronesi P, Galimberti V, Goldhirsch A, Veronesi U, Paganelli G. Sentinel lymph node biopsy in pregnant patients with breast cancer. Eur J Nucl Med Mol Imaging 37: 78-83, 2010

339. Viale G, Giobbie-Hurder A, Gusterson BA, Maiorano E, Mastropasqua MG, Sonzogni A, Mallon E, Colleoni M, Castiglione-Gertsch M, Regan MM, Price KN, Brown RW, GolouhR, Crivellari D, Karlsson P, Öhlschlegel C, Gelber RD, Goldhirsch A & Coates AS. Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. Ann Oncol 21: 245-254, 2010

340. Munzone E, Di Pietro A, Goldhirsch A, Minchella I, Verri E, Cossu Rocca M, Marenghi C, Curigliano G, Radice D, Adamoli L, Nolè F. Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: A mono-institutional case-series report. Breast 19: 33-37, 2010

341. Maiorano E, Regan MM, Viale G, Mastropasqua MG, Colleoni M, Castiglione-Gertsch M, Price KN, Gelber RD, Goldhirsch A, Coates AS. Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy. Breast Cancer Res Treat 121: 211-218, 2010

342. Guerrieri-Gonzaga A, Botteri E, Lazzeroni M, Rotmensz N, Goldhirsch A, Varricchio C, Serrano D, Cazzaniga M, Bassi F, Luini A, Bagnardi V, Viale G, Mora S, Bollani G, Albertazzi E, Bonanni B, Decensi A. Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational study. Ann Oncol 21: 949-954, 2010

343. Iorfida M, Bagnardi V, Balduzzi A, Dellapasqua S, Cardillo A, Luini A, Intra M, Minchella I, Veronesi P, Viale G, Goldhirsch A, Colleoni M. Preoperative therapy with trastuzumab and oral vinorelbine (+/- endocrine therapy) in patients with HER2-positive breast cancer. Breast 19: 128-132, 2010

344. Colleoni M, Cole BF, Viale G, Regan MM, Price KN, Maiorano E, Mastropasqua MG, Crivellari D, Gelber RD, Goldhirsch A, Coates AS, and Gusterson BA. Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol 28: 2966-2973, 2010

345. Botteri E, Sandri MT, Bagnardi V, Munzone E, Zorzino L, Rotmensz N, Casadio C, Cassatella MC, Esposito A, Curigliano G, Salvatici M, Verri E, Adamoli L, Goldhirsch A, Nolè F. Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer. Breast Cancer Res Treat 122: 211-217, 2010

346. Paridaens RJ, Gelber S, Cole BF, Gelber RD, Thürlimann B, Price KN, Holmberg SB, Crivellari D, Coates AS, Goldhirsch A. Adjuvant!(©) Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 123: 303-310, 2010

347. Botteri E, Bagnardi V, Goldhirsch A, Viale G, Rotmensz N. Axillary lymph node involvement in women with breast cancer: does it depend on age? Clin Breast Cancer 10: 318-321, 2010

348. Colleoni M, Bagnardi V, Rotmensz N, Viale G, Mastropasqua M, Veronesi P, Cardillo A, Torrisi R, Luini A, Goldhirsch A. A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete

28

remission after preoperative chemotherapy for breast cancer. Eur J Cancer 46: 2216-2224, 2010

349. Phillips KA, Ribi K, Sun Z, Stephens A, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. Breast 19: 388-395, 2010

350. Munzone E, Nolé F, Goldhirsch A, Botteri E, Esposito A, Zorzino L, Curigliano G, Minchella I, Adamoli L, Cassatella MC, Casadio C, Sandri MT. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. Clin Breast Cancer 10: 392-397, 2010

351. Balduzzi A, Leonardi MC, Cardillo A, Orecchia R, Dellapasqua S, Iorfida M, Goldhirsch A, Colleoni M. Timing of adjuvant systemic therapy and radiotherapy after breast-conserving surgery and mastectomy. Cancer Treat Rev 36: 443-450, 2010

352. Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Veronesi P, Torrisi R, Montagna E, Luini A, Intra M, Gentilini O, Ghisini R, Goldhirsch A, Colleoni M. Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann Oncol 21: 1974-1981, 2010

353. Montagna E, Bagnardi V, Rotmensz N, Viale G, Pruneri G, Veronesi P, Cancello G, Balduzzi A, Dellapasqua S, Cardillo A, Luini A, Zurrida S, Gentilini O, Mastropasqua MG, Bottiglieri L, Iorfida M, Goldhirsch A, Colleoni M. Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. Breast Cancer Res Treat 124: 689-699, 2010

354. Torrisi R, Cardillo A, Cancello G, Dellapasqua S, Balduzzi A, Ghisini R, Luini A, Veronesi P, Viale G, Goldhirsch A, Colleoni M. Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer. Clin Breast Cancer 10: 483-488, 2010

355. Phillips KA, Aldridge J, Ribi K, Sun Z, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J. Cognitive function in postemenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. Breast Cancer Res Treat 126: 221-226, 2011

356. Curigliano G, Viale G, Ghioni M, Jungbluth AA, Bagnardi V, Spagnoli GC, Neville AM, Nolè F, Rotmensz N & Goldhirsch A. Cancer-testis antigen expression in triple-negative breast cancer. Ann Oncol 22: 98-103, 2011

357. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini Jl, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R; for the Herceptin Adjuvant (HERA) Trial Study Team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomized controlled trial. Lancet Oncol 12: 236-244, 2011

358. Colleoni M, Giobbie-Hurder A, Regan MM, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Láng I, Smith I, Chirgwin J, Pienkowski T, Wardley A, Price KN, Gelber RD, Coates AS, Goldhirsch A. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 29: 1117-1124, 2011

359. Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Montagna E, Dellapasqua S, Iorfida M, Cardillo A, Veronesi P, Luini A, Intra M, Gentilini O, Scarano E, Goldhirsch A, Colleoni M. Prognosis in women with small (T1mic, T1a, T1b) node-negative

29

operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Res Treat 127: 713-720, 2011

360. Torrisi R, Bagnardi V, Rotmensz N, Scarano E, Iorfida M, Veronesi P, Luini A, Viale G, Santoro A, Colleoni M, Goldhirsch A. Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer. Breast Cancer Res Treat 126: 431-441, 2011

361. Karlsson P, Cole BF, Colleoni M, Roncadin M, Chua BH, Murray E, Price KN, Castiglione-Gertsch M, Goldhirsch A, Gruber G; for the International Breast Cancer Study Group. Timing of radiotherapy and outcome in patients receiving adjuvant endocrine therapy. Int J Radiat Oncol Biol Phys 80: 398-402, 2011

362. Catania C, De Pas T, Minchella I, De Braud F, Micheli D, Adamoli L, Spitaleri G, Noberasco C, Milani A, Zampino MG, Toffalorio F, Radice D, Goldhirsch A, Nolè F. «Waiting and the waiting room: how do you experience them?» Emotional implications and suggestions from patients with cancer. J Cancer Educ 26: 388-394, 2011

363. Torrisi R, Montagna E, Scarano E, Dellapasqua S, Cancello G, Iorfida M, Luini A, Veronesi P, Viale G, Goldhirsch A, Colleoni M. Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluorouracil (CCF) with and without endocrine therapy in locally advanced primari or recurrent breast cancer. Breast 20: 34-38, 2011

364. Farante G, Zurrida S, Galimberti V, Veronesi P, Curigliano G, Luini A, Goldhirsch A, Veronesi U. The management of ductal intraepithelial neoplasia (DIN): open controversies and guidelines of the Istituto Europeo di Oncologia (IEO), Milan, Italy. Breast Cancer Res Treat 128: 369-378, 2011

365. Lohsiriwat V, Curigliano G, Rietjens M, Goldhirsch A, Petit JY. Autologous fat transplantation in patients with breast cancer: «silencing» or «fueling» cancer recurrence? Breast 20: 351-357, 2011

366. Dellapasqua S, Mazza M, Rosa D, Ghisini R, Scarano E, Torrisi R, Maisonneuve P, Viale G, Cassano E, Veronesi P, Luini A, Goldhirsch A, Colleoni M. Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer. Breast 20: 319-323, 2011

367. Aebi S, Sun Z, Braun D, Price KN, Castiglione-Gertsch M, Rabaglio M, Gelber RD, Crivellari D, Lindtner J, Snyder R, Karlsson P, Simoncini E, Gusterson BA, Viale G, Regan MM, Coates AS & Goldhirsch A. Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX. Ann Oncol 22: 1981-1987, 2011

368. Viale G, Regan MM, Dell’Orto P, Pastropasqua MG, Maiorano E, Rasmussen BB, Macgrogan G, Forbes JF, Paridaens RJ, Colleoni M, Láng I, Thürlimann B, Mouridsen H, Mauriac L, Gelber RD, Price KN, Goldhirsch A, Gusterson BA, Coates AS; for the BIG 1-98 Collaborative and International Breast Cancer Study Groups. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol 22: 2201-2207, 2011

369. Karlsson P, Sun Z, Braun D, Price KN, Castiglione-Gertsch M, Ragablio M, Gelber RD, Crivellari D, Collins J, Murray E, Zaman K, Colleoni M, Gusterson BA, Viale G, Regan MM, Coates AS & Goldhirsch A. Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. Ann Oncol 22: 2216-2226, 2011

370. Curigliano G, Bagnardi V, Viale G, Fumagalli L, Rotmensz N, Aurilio G, Locatelli M, Pruneri G, Giudici S, Bellomi M, Della Vigna P, Monfardini L, Orsi F, Nolè F, Munzone E, Goldhirsch A. Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol 22: 2227-2233, 2011

30

371. Pagani O, Partridge A, Korde L, Badve S, Bartlett J, Albain K, Gelber R, Goldhirsch A. Pregnancy after breast cancer: if you wish, ma’am. Breast Cancer Res Treat 129: 309-317, 2011

372. Montagna E, Bagnardi V, Rotmensz N, Viale G, Cancello G, Mazza M, Cardillo A, Ghisini R, Galimberti V, Veronesi P, Monti S, Luini A, Raviele PR, Mastropasqua MG, Goldhirsch A, Colleoni M. Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation. Breast Cancer Res Treat 129: 867-875, 2011

373. Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B; for the members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group (IBCSG). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol 12: 1101-1108, 2011

374. Curigliano G, Goldhirsch A. The triple-negative subtype: new ideas for the poorest prognosis breast cancer. J Natl Cancer Inst Monogr 2011: 108-110, 2011

375. Montagna E, Bagnardi V, Rotmensz N, Viale G, Renne G, Cancello G, Balduzzi A, Scarano E, Veronesi P, Luini A, Zurrida S, Monti S, Mastropasqua MG, Bottiglieri L, Goldhirsch A, Colleoni M. Breast cancer subtypes and outcome after local and regional relapse. Ann Oncol 23: 324-331, 2012

376. Curigliano G, Locatelli M, Fumagalli L, Brollo J, Munzone E, Nolé F, Criscitiello C, Goldhirsch A. Targeting the subtypes of breast cancer: rethinking investigational drugs. Expert Opin Investig Drugs 21: 191-204, 2012

377. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M; on behalf of the NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomized, open-label, multicentre, phase 3 trial. Lancet 379: 633-640, 2012

378. Montemurro F, Rossi V, Rocca MC, Martinello R, Verri E, Redana S, Adamoli L, Valabrega G, Sapino A, Aglietta M, Viale G, Goldhirsch A, Nolè F. Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. Cancer 118: 17-26, 2012

379. Chirgwin J, Sun Z, Smith I, Price KN, Thürlimann B, Ejlertsen B, Bonnefoi H, Regan MM, Goldhirsch A, Coates AS, for the BIG 1-98 Collaborative and International Breast Cancer Study Groups. The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. Breast Cancer Res Treat 131: 295-306, 2012

380. Ribeiro JT, Macedo LT, Curigliano G, Fumagalli L, Locatelli M, Dalton M, Quintela A, Carvalheira JB, Manunta S, Mazzarella L, Brollo J, Goldhirsch A. Cytotoxic drugs for patients with breast cancer in the era of targeted treatments: back to the future? Ann Oncol 23: 547-555, 2012

381. Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell’Orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G; on behalf of the Breast International Group (BIG) 1-98 Collaborative Group. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst 104: 441-451, 2012

382. Didier F, Arnaboldi P, Gandini S, Maldifassi A, Goldhirsch A, Radice D, Minotti I, Ballardini B, Luini A, Santillo B, Rietjens M, Petit JY. Why do women accept to undergo a nipple sparing

31

mastectomy or to reconstruct the nipple areola complex when nipple sparing mastectomy is not possible? Breast Cancer Res Treat 132: 1177-1184, 2012

383. Montagna E, Cancello G, Bagnardi V, Pastrello D, Dellapasqua S, Perri G, Viale G, Veronesi P, Luini A, Intra M, Calleri A, Rampinelli C, Goldhirsch A, Bertolini F, Colleoni M. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity. Clin Breast Cancer 12: 207-214, 2012

384. Colleoni M, Rotmensz N, Maisonneuve P, Mastropasqua MG, Luini A, Veronesi P, Intra M, Montagna E, Cancello G, Cardillo A, Mazza M, Perri G, Iorfida M, Pruneri G, Goldhirsch A, Viale G. Outcome of special types of luminal breast cancer. Ann Oncol 23: 1428-1436, 2012

385. Azim HA Jr, Botteri E, Renne G, Dell’Orto P, Rotmensz N, Gentilini O, Sangalli C, Pruneri G, Di Nubila B, Locatelli M, Sotiriou C, Piccart M, Goldhirsch A, Viale G, Peccatori FA. The biological features and prognosis of breast cancer diagnosed during pregnancy: A case-control study. Acta Oncol 51: 653-661, 2012

386. Botteri E, Disalvatore D, Curigliano G, Brollo J, Bagnardi V, Viale G, Orsi F, Goldhirsch A, Rotmensz N. Biopsy of liver metastasis for women with breast cancer: Impact on survival. Breast 21: 284-288, 2012

387. Dellapasqua S, Bagnardi V, Bertolini F, Sandri MT, Pastrello D, Cancello G, Montagna E, Balduzzi A, Mancuso P, Luini A, Goldhirsch A, Colleoni M. Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab. Breast 21: 309-313, 2012

388. Iorfida M, Maiorano E, Orvieto E, Maisonneuve P, Bottiglieri L, Rotmensz N, Montagna E, Dellapasqua S, Veronesi P, Galimberti V, Luini A, Goldhirsch A, Colleoni M, Viale G. Invasive lobular breast cancer: subtypes and outcome. Breast Cancer Res Treat 133: 713-723, 2012

389. Munzone E, Botteri E, Sciandivasci A, Curigliano G, Nolé F, Mastropasqua M, Rotmensz N, Colleoni M, Esposito A, Adamoli L, Luini A, Goldhirsch A, Viale G. Progonostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer. Breast Cancer Res Treat 2012 Apr 1 [Epub ahead of print]

390. Ribi K, Aldridge J, Phillips KA, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J. Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. Br J Cancer 2012 Apr 24 doi: 10.1038/bjc.2012.156 [Epub ahead of print]

391. Botteri E, Gentilini O, Rotmensz N, Veronesi P, Ratini S, Fraga-Guedes C, Toesca A, Sangalli C, Del Castillo A, Rietjens M, Viale G, Orecchia R, Goldhirsch A, Veronesi U. Mastectomy without radiotherapy: outcome analysis after 10 years of follow-up in a single institution. Breast Cancer Res Treat 2012 Apr 26 [Epub ahead of print]

392. Brollo J, Curigliano G, Disalvatore D, Marrone BF, Criscitiello C, Bagnardi V, Kneubil MC, Fumagalli L, Locatelli M, Manunta S, Goldhirsch A. Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: A systematic review of randomized controlled trials. Cancer Treat Rev 2012 Apr 26 [Epub ahead of print]

393. Munzone E, Botteri E, Esposito A, Sciandivasci A, Franchi D, Pruneri G, Rotmensz N, Curigliano G, Adamoli L, Bocciolone L, Goldhirsch A, Nolé F. Outcome and clinical-biological characteristics of patients with advanced breast cancer undergoing removal of ovarian/pelvic metastases. Ann Oncol 2012 Apr 29 [Epub ahead of print]

394. Huober J, Gelber S, Goldhirsch A, Coates AS, Viale G, Ohlschlegel C, Price KN, Gelber RD, Regan MM, Thürlimann B. Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. Ann Oncol 2012 Jun 14 [Epub ahead of print]

32

EBCTCG Overview

1. Early Breast Cancer Trialists’ Collaborative Group [Henderson IC, Mouridsen H (co-chairmen), Goldhirsch A, Gelber RD, et al, members]. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 319: 1681-1692, 1988

2. Early Breast Cancer Trialists’ Collaborative Group (Goldhirsch A, Chairman Update Committee): Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 1-15 & 71-85, 1992

3. Early Breast Cancer Trialists’ Collaborative Group (Goldhirsch A, Chairman Update Committee): Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 348: 1189-1196, 1996

4. Early Breast Cancer Trialists’ Collaborative Group (Goldhirsch A, Chairman Update Committee). Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451-1467, 1998

5. Early Breast Cancer Trialists’ Collaborative Group (Goldhirsch A, Chairman Update Committee). Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930-942, 1998

6. Early Breast Cancer Trialists’ Collaborative Group, Clarke M, Coates AS, Darby SC, Davies C, Gelber RD, Godwin J, Goldhirsch A, Gray R, Peto R, Pritchard KI, Wood WC. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 371: 29-40, 2008

Editorials

1. Gelber RD, Goldhirsch A. Can a clinical trial be the treatment of choice for patients with cancer? (Editorial). J Natl Cancer Inst 80: 886-887, 1988

2. Goldhirsch A, Valagussa P. Old and new trends in the adjuvant treatment of early breast cancer (Editorial). Ann. Oncol 2: 320-322, 1991

3. Gelber RD, Coates AS, Goldhirsch A. Adjuvant therapy for breast cancer: the overview (Editorial). B Med J 304: 859-860, 1992

4. Goldhirsch A, Gelber RD. Understanding adjuvant chemotherapy for breast cancer (Editorial). N Engl J Med 330: 1308-1309, 1994

5. Gelber RD, Goldhirsch A. Radiotherapy to the conserved breast: is it avoidable if the cancer is small (Editorial). J Natl Cancer Inst 86: 652-654, 1994

6. Colleoni M, Goldhirsch A. Adjuvant chemotherapy in breast cancer: back to the future. (Editorial). Onkologie 26: 111-112, 2003

7. Goldhirsch A, Gelber RD. Life with consequences of breast cancer: pregnancy during and after endocrine therapies. (Editorial) Breast 13: 443-445, 2004

8. Colleoni M, Gelber S & Goldhirsch A. Treatment of advanced breast cancer: the good, the bad and the ugly. (Editorial) Ann Oncol 16: 1219-1221, 2005

33

9. Goldhirsch A, Gelber RD and Coates AS. What are the long-term effects of chemotherapy and hormonal therapy for early breast cancer? Nat Clin Pract Oncol 2: 440-441, 2005

10. Goldhirsch A, Gelber RD. Back to the future (Editorial). Références en Gynécologie Obstétrique 11: S13-S15, 2005

34

Reviews and book chapters

1. Goldhirsch A, Cioccari L, Cavalli F. Il Tamoxifen: un antiestrogeno nel trattamento del carcinoma mammario metastatizzante. Riv Med della Svizzera Italiana 12: 61-63, 1978

2. Goldhirsch A. Tumori maligni testicolari. Riv Med della Svizzera Italiana 12: 303-304, 1978

3. Goldhirsch A, Cavalli F. Carcinoma bronchiale a piccole cellule: diagnosi, trattamento e prospettive. Riv Med della Svizzera Italiana 13: 9-11, 1979

4. Goldhirsch A, Joss R, Greiner R, Brunner KW. Das Ovarialkarzinom. Neue prognostische und therapeutische Gesichtspunkte. Schweiz med Wschr 110: 1597-605, 1980

5. Greiner R, Schibler C, Stoller C, Zimmermann A, Goldhirsch A. Maligne Non-Hodgkin Lymphome der ORL-Region und des Magen-Darm-Traktes. Ergebnisse, Indikation und Technik der Strahlentherapie. Schweiz med Wschr 110: 1170-77, 1980

6. Greiner R, Schibler C, Stoller C, Zimmermann A, Goldhirsch A. Maligne Non-Hodgkin Lymphome des Waldeyerschen Rings, der Nasennebenhöhlen und der Speicheldrüsen. Strahlentherapie 156: 742-49, 1980

7. Joss R, Goldhirsch A, Brunner KW. Das anaplastische kleinzellige Bronchuskarzinom. Dtsch med Wschr 105: 732-35, 1980

8. Joss R, Goldhirsch A, Brunner KW. Das nicht-kleinzellige Bronchuskarzinom, Diagnose, Behandlung und Prognose. Dtsch med Wschr 105: 766-70, 1980

9. Joss R, Goldhirsch A, Brunner KW. Komplikationen im Bereiche der Niere und der ableitenden Harnwege im Verlauf von Tumorkrankeiten. Schweiz med Wschr 110: 390-404, 1980

10. Joss R, Tschopp L, Goldhirsch A, Brunner KW. Das maligne Melanom, Spontanverlauf, Therapie und Prognose. Schweiz med Wschr 110: 710-15, 1980

11. Brunner KW, Goldhirsch A, Joss R. Die Chemotherapie des Ovarialkarzinoms: Neue Aspekte. Schw Rundschau Med (Praxis) 18: 809-14, 1981

12. Brunner KW, Goldhirsch A, Joss R, Sonntag RW, Tschopp L. Resultate und Indikationen der adjuvanten Chemotherapie beim Mammakarzinom. Schweiz med Wschr 111: 838-45, 1981

13. Goldhirsch A, Joss R, Cavalli F, Brunner KW. Etoposid. Mono- und Polychemotherapie des Bronchialkarzinoms. Aktuelle Onkologie 4: 51-58, 1981

14. Goldhirsch A, Leuenberger U, Cavalli F. Hormonrezeptoren und Mammakarzinom. Gynäk Rdsch 21: 18-23, 1981

15. Goldhirsch A, Leuenberger U, Cavalli F. Recettori ormonali e carcinoma mammario. Riv Med della Svizzera Italiana 15: 401-403, 1981

16. Goldhirsch A, Joss R, Cavalli F, Sonntag RW, Ryssel HJ, Brunner KW. Etoposid. Ein neues Zytostatikum mit hoher Wirksamkeit beim anaplastischen kleinzelligen Bronchuskarzinom, bei anderen soliden Tumoren und bei Hämoblastosen. Dtsch med Wschr 106: 1105-109, 1981

17. Greiner R, Egli R, Garavaglia G, Goldhirsch A. Die Bedeutung der Strahlentherapie bei der Behandlung der Ovarialkarzinome - Indikationen, Techniken, Resultate. Schw Rundschau Med (Praxis) 18: 815-22, 1981

18. Joss R, Nöthiger F, Greiner R, Goldhirsch A, Brunner KW. Kolorektale Karzinome. Fortschritte und ungelöste Probleme. Schweiz med Wschr 111: 687-705, 1981

35

19. Joss R, Goldhirsch A, Brunner KW. Epidemiologie, Spontanverlauf, klinische Aspekte und präoperative Abklärung des Ovarialkarzinoms. Schw Rundschau Med (Praxis) 18: 798-802, 1981

20. Joss R, Leuenberger U, Zava DT, Goldhirsch A, Brunner KW. Neuere Aspekte in der Behandlung des Mammakarzinoms. Schw Rundschau Med (Praxis) 18: 1638-46, 1981

21. Joss R, Salonen K, Goldhirsch A, Brunner KW. Therapie und Prognose der oberen Einflussstauung beim anaplastischen kleinzelligen Bronchuskarzinom. Klin Wschr 59: 385-89, 1981

22. Joss R, Goldhirsch A, Tschopp L, Brunner KW. Gastrointestinale Tumoren. Prognostische Faktoren und Stand der Chemotherapie. Dtsch med Wschr 106: 1664-69, 1981

23. Joss R, Goldhirsch A, Sonntag RW, Brunner KW. Metastasen im Bereich des zentralen Nervensystems beim anaplastischen kleinzelligen Bronchuskarzinom. Schweiz med Wschr 111: 48-52, 1981

24. Joss R, Galeazzi R, Gervasi A, Godat F, Goldhirsch A, Brunner KW. Nausea und Erbrechen bei der Chemotherapie maligner Tumoren. Schweiz med Wschr 111: 1614-22, 1981

25. Cavalli F, Goldhirsch A, Jungi WF, Martz G, Alberto P. Low- versus high-dose medroxyprogesterone acetate in the treatment of advanced breast cancer. International Symposium on Medroxyprogesterone Acetate. F. Cavalli, WL. McGuire, F. Pannuti, A. Pellegrini, G. Robustelli della Cuna Eds. Excerpta Medica, Amsterdam, 1982, pp 224-33

26. Joss R, Goldhirsch A, Kappeler M, Nöthiger F, Greiner R, Brunner KW. Das Magenkarzinom. Spontanverlauf, Behandlung und Prognose. Schweiz med Wschr 112: 290-96, 1982

27. Jungi WF, Senn HJ, Goldhirsch A, Cavalli F. Post-operative adjuvant trials in breast cancer- the Swiss Group and the Ludwig International Group. In: Clinical Trials in Early Breast Cancer, M. Baum, R.Kay, H. Scheuerlen, Eds. Experimenta Suppl, Birkhäuser Verlag 41, 1982, pp 613-15

28. Sonntag RW, Joss R, Goldhirsch A, Brunner KW. Prognostische Faktoren beim metastasierenden nicht-seminomatösen Hodenkarzinom. Beitrag zur Onkologie, Karger Verlag, Basel, 1982, pp 250-56

29. Brunner KW, Joss R, Goldhirsch A. Der Stand der Chemotherapie beim operablen nicht-kleinzelligen Bronchuskarzinom. Schw Rundschau Med (Praxis) 32: 1057-62, 1983

30. Goldhirsch A. Studien der Ludwig-Gruppe über die adjuvante Therapie beim Mammakarzinom. In: Adjuvante Therapie des Mammakarzinoms - Expertengespräch 1982. V. Diehl, W. Jonat, H. Maass, GA. Nagel Eds. Kehrer Verlag, Freiburg, 1983, pp 129-36

31. Joss R, Gervasi A, Goldhirsch A, Brunner KW. Können kleinzellige Bronchuskarzinome heute geheilt werden ? Schw Rundschau Med (Praxis) 32: 464-71, 1983

32. Joss R, Bleher EA, Goldhirsch A, Kaufmann M, Brunner KW. Adjuvante Therapien beim operablen nicht-kleinzelligen Bronchuskarzinom. Schw Rundschau Med (Praxis) 32: 553-60, 1983

33. Joss R, Galeazzi RL, Goldhirsch A, Ryssel HJ, Brunner KW. Nausea und Erbrechen bei Tumorpatienten. Schw Rundschau Med (Praxis) 77: 1391-96, 1983

34. Cavalli F, Goldhirsch A, Joss R, Brunner KW. Hormone-chemotherapy in treatment of advanced breast cancer. In: Cancer Chemotherapy and Selective Drug Development, KR. Harrap. W. Davis, AH. Calvert Eds, Martinus Nijhoff, Boston, 1984, pp 95-104

36

35. Cavalli F, Goldhirsch A, Joss R. Single-agent activity and European experience with etoposide in the treatment of non-small cell lung cancer. In: Etoposide (VP-16), Academic Press, 1984, pp 163-69

36. Goldhirsch A, Joss R, Cavalli F. Etoposide in the treatment of non-small cell lung cancer. In: Etoposide (VP-16), Academic Press, 1984, pp 209-14

37. Goldhirsch A, for the Ludwig Breast Cancer Study Group. Adjuvant therapy for postmenopausal women with operable breast cancer. Part I- A randomized trial of chemoendocrine versus mastectomy alone. In: Adjuvant Therapy of Cancer IV, SE. Jones and SE Salmon Eds, Grune & Stratton, Orlando, 1984, pp 379-91

38. Joss RA, Cavalli F, Goldhirsch A, Mermillod B, Brunner KW. New agents in non-small cell lung cancer. Cancer Treat Rev 11: 205-36, 1984

39. Goldhirsch A, for the Ludwig Breast Cancer Study Group. Ludwig Breast Cancer Trials III and IV: Adjuvant endocrine treatment in postmenopausal patients. In: Adjuvant Chemotherapy of Breast cancer. Recent Results in Cancer Research, HJ. Senn Ed, Springer Verlag, Berlin, 1984, pp 204-209

40. Brunner KW, Goldhirsch A, Greiner R. Die Chemotherapie als Primärtherapie bei nicht radikal operiertem Ovarialkarzinom. Onkologie 8: 347-55, 1985

41. Goldhirsch A, Almendral AC. Maligne gynäkologische Tumoren (Genitalkarzinome). In: Internistische Krebstherapie. KW. Brunner, GA. Nagel, Eds, Springer Verlag, Berlin, 1985, pp 388-417

42. Goldhirsch A, Greiner R, Davis B. Chemotherapy followed by whole-abdominal radiation therapy for ovarian cancer. In: Ovarian Cancer. SE. Alberts and EA. Surwit, Eds, Matinus Nijhoff, Boston, 1985, pp 213-26

43. Goldhirsch A, for the Ludwig Breast Cancer Study Group. Adjuvant treatment in operable breast cancer. J Steroid Biochem 23: 1155-60, 1985

44. Varini M, Goldhirsch A, Jungi WF, Martz G, Mermillod B, Alberto P, Cavalli F, for the SAKK. Randomisierte Studie mit zwei verschiedenen Dosierungen von Medroxy-progesteronacetat (MPA) in der Behandlung des metastasierenden Mammakarzinoms. In: Medroxyprogesteronacetat (MPA) in der Onkologie. CG. Schmidt, H. Schmidt-Matthiesen, Eds, Schattauer, Stuttgart, 1985, pp 173-85

45. Goldhirsch A, for the Ludwig Breast Cancer Study Group. Perioperative and conventionally-timed chemotherapy in operable breast cancer. In: Perioperative Chemotherapy. Recent Results in Cancer Research. . U. Metzger, F. Largiader, HJ. Senn, Eds, Springer Verlag, Berlin, 1985, pp 106-13

46. Cavalli F, Goldhirsch A, Gelber RD, for the Ludwig Breast Cancer Study Group. The Ludwig Breast Cancer Studies: Adjuvant therapy for early breast cancer. In: Estrogen/Antiestrogen Action and Breast Cancer Therapy. . VC. Jordan Ed. University of Wisconsin Press, 1986, pp 460-69

47. Goldhirsch A, Gelber RD, Davis BW. Adjuvant chemotherapy trials in breast cancer: an appraisal and lessons for patient care outside the trials. In: Clinical Surgery International. Breast Diseases, vol 10, JF. Forbes Ed, Churchill Livingstone, Edinburgh, 1986, pp 123-38

48. Gelber RD, Goldhirsch A. The requirement for clinical trials in breast cancer. In: Clinical Surgery International. Breast Disease, Vol 10, JF. Forbes Ed, Churchill Livingstone, Edinburgh, 1986, pp 106-22

49. Gelber RD, Goldhirsch A. Methodology of clinical trials investigating endocrine mechanisms in breast cancer. In: Endocrine Therapy of Breast Cancer. F. Cavalli Ed, ESO, European School of Oncology Monographs, U. Veronesi, Series Ed. Springer Verlag, Berlin, 1986, pp 51-77

37

50. Goldhirsch A, Gelber RD, Mouridsen H. Endocrine aspects in adjuvant therapy for early breast cancer. In: Endocrine Therapy of Breast Cancer. F. Cavalli Ed, ESO, European School of Oncology Monographs, U. Veronesi, Series Ed. Springer Verlag, Berlin, 1986, pp 91-107

51. Goldhirsch A, Gelber RD. Endocrine adjuvant therapy in breast cancer: the experience of the Ludwig Group. Proc First International Congress on Cancer and Hormones. S. Iacobelli, EE. Beulieu, W. McGuire, Eds, Parthenon Press, 1986, pp 479-90

52. Gelber RD, Goldhirsch A. Methodological issues in neoadjuvant chemotherapy trials. In: Neo-Adjuvant Chemotherapy: First International Congress. C. Jacquillat, M. Weil, D. Khayat, Eds, Colloque INSERM, Vol 137, John Libbey Eurotext, 1986, pp 798-809

53. Goldhirsch A. Future uses of regional perfusion. In: Die Perfusionsbehandlung des Extremitätsmelanoms: Indikationen, Technik, Komplikationen und Ergebnisse der regionalen Perfusionsbehandlung des malignen Melanoms der Extremitäten. B. Nachbur Ed, Hans Huber Verlag, Bern, 1986, pp 86-87

54. Joss RA, Cavalli F, Goldhirsch A, Brunner KW. New drugs in small-cell lung cancer. Cancer Treat Rev 13: 157-76, 1986

55. Goldhirsch A, Gelber RD. Perioperative and conventionally timed chemotherapy in operable breast cancer: The Ludwig Breast Cancer Study V. In: Perioperative (Neoadjuvant) Chemotherapy. J. Ragaz, PR. Band, JH. Goldie, Eds. Springer Verlag, Berlin, 1986, pp 103-12

56. Gelber RD, Goldhirsch A. Evaluating the benefits of therapies for breast cancer. In: Endocrine Therapy for Breast Cancer II. F. Cavalli Ed. ESO, European School of Oncology Monographs, U. Veronesi Series Ed. Springer Verlag, Berlin, 1987, pp 21-32

57. Goldhirsch A, Gelber RD, Mouridsen H. Adjuvant chemotherapy in premenopausal patients: a more complicated form of oophorectomy? In: Endocrine Therapy for Breast Cancer II. F. Cavalli Ed. ESO, European School of Oncology Monographs, U. Veronesi Series Ed. Springer Verlag, Berlin, 1987, pp 11-19

58. Goldhirsch A, Gelber RD, for the Ludwig Breast Cancer Study Group. Adjuvant therapy for breast cancer: the Ludwig Breast Cancer Trials 1987. In: Adjuvant Therapy of Cancer V. SE. Salmon Ed, Grune & Stratton, Orlando, 1987, pp 297-309

59. Gelber RD, Goldhirsch A, Castiglione M, Isley M, Price K, Coates A, for the Ludwig Breast Cancer Study Group. Time without symptoms and toxicity (TWiST): A quality-of-life-oriented endpoint. In: Adjuvant Therapy of Cancer V. SE. Salmon Ed, Grune & Stratton, Orlando, 1987, pp 455-65

60. Richner J, Buser K, Goldhirsch A. Interferons (INFs) intraperitoneally in advanced cancer of the ovary: A new route to success? Interferons Today and Tomorrow 5: 4-5, 1987

61. Goldhirsch A, Castiglione M. Die adjuvante Behandlung des Mammakarzinoms. Gynäkol Rdsch 28 (suppl 1) 65-75, 1988

62. Öberg K, Goldhirsch A, Neville AM. Diagnosis and treatment of malignant disorders of the adrenal gland. In: Textbook of Uncommon Cancer. CJ. Williams, JG. Krikorian, MR. Green, D. Raghavan Eds, John Wiley & Sons, New York, 1988, pp 731-62

63. Goldhirsch A, Castiglione M, Neuenschwander H. Adjuvante Therapie nach brusterhaltender Operation des Mammakarzinoms: Vorrang der Chemo- oder der Strahlentherapie? Ther Umschau 45: 383-88, 1988

64. Goldhirsch A, Gelber RD. Treatment of overt metastatic breast cancer In: Bailliere's Clinical Oncology. International Practice and Research. Breast Cancer. U. Veronesi Ed, 1988, pp 215-29

38

65. Goldhirsch A, Bruntsch U. Mammakarzinom ohne Lymphknotenbefall. Adjuvante systemische Therapie für alle Patientinnen? Münch med Wschr 130: 783-84, 1988

66. Nachbur B, Vogt W, Goldhirsch A. Treatment of soft tissue malignancies of the extremities by regional perfusion In: Regional Chemotherapy. U Laffer, W. Weber-Stadelmann, U. Metzger, Eds. Antibiot Chemother. (Karger Verlag, Basel) 40: 77-93, 1988

67. Goldhirsch A, Gelber RD. Randomized perioperative therapy in operable breast cancer: the Ludwig Trial V. In: Adjuvant Therapy of Primary Breast cancer. Recent Results in Cancer Research, HJ. Senn, A. Goldhirsch, RD. Gelber, B. Osterwalder Eds, Springer Verlag, Berlin, 1989, pp. 43-53

68. Goldhirsch A, Gelber RD. Adjuvant chemo-endocrine therapy or endocrine therapy alone for postmenopausal patients: Ludwig Studies III and IV. In: Adjuvant Therapy of Primary Breast cancer. Recent Results in Cancer Research, HJ. Senn, A. Goldhirsch, RD. Gelber, B. Osterwalder Eds, Springer Verlag, Berlin, 1989, pp. 153-62

69. Gelber RD, Goldhirsch A. Methods for assessing treatment efficacy in trials of adjuvant therapy for breast cancer. In: Adjuvant Therapy of Primary Breast cancer. Recent Results in Cancer Research, HJ. Senn, A. Goldhirsch, RD. Gelber, B. Osterwalder Eds, Springer Verlag, Berlin, 1989, pp. 211-19

70. Gelber RD, Goldhirsch A, Simes RJ, Glasziou P, Castiglione M. Integration of quality-of-life issues into clinical trials of breast cancer. In: Endocrine Therapy for Breast Cancer III. F. Cavalli Ed. ESO, European School of Oncology Monographs, U. Veronesi Series Ed. Springer Verlag, Berlin, 1989, pp 27-36

71. Goldhirsch A, Gelber RD. Adjuvant systemic therapy for breast cancer patients without lymph node metastases (N-). In: Endocrine Therapy for Breast Cancer III. F. Cavalli Ed. ESO, European School of Oncology Monographs, U. Veronesi Series Ed. Springer Verlag, Berlin, 1989, pp 37-43

72. Gelber RD, Goldhirsch A. Statistics in clinical trials. In: Data Management and Clinical Trials. N Rotmensz, Ed, Elsevier Science Publishers B.V. Amsterdam, 1989, pp 175-204

73. Gelber RD, Goldhirsch A. Clinical trials for clinicians. Chest 96 (suppl): 97S-101S, 1989

74. Castiglione M, Goldhirsch A. Die adjuvante Behandlung des Mammakarzinoms. In: Die Systemtherapie des Mammakarzinoms; Internationales Symposium des Westdeutschen Tumorzentrums Essen; R. Becher, K. Höffken Eds. W. Zuckschwerdt Verlag, München, 1989, pp 30-51

75. Castiglione M, Goldhirsch A. Lebensqualität bei zytostatischer Chemotherapie: Messbarkeit und Beurteilung. In: Die Systemtherapie des Mammakarzinoms; Internationales Symposium des Westdeutschen Tumorzentrums Essen; R Becher, K. Höffken Eds. W. Zuckschwerdt Verlag, München, 1989, pp 135-140

76. Goldhirsch A, Gelber RD, Castiglione M. Adjuvant Chemotherapy in premenopausal breast cancer patients is effective by means other than ovarian function suppression. In: Endocrine Therapy for Breast Cancer IV. A. Goldhirsch Ed. ESO, European School of Oncology Monographs, U. Veronesi Series Ed. Springer Verlag, Berlin, 1990, pp 77-86

77. Gelber RD, Goldhirsch A. Alternative methods for describing treatment benefit including quality-of-life considerations. In: Endocrine Therapy for Breast Cancer IV. A. Goldhirsch Ed. ESO, European School of Oncology Monographs, U. Veronesi Series Ed. Springer Verlag, Berlin, 1990, pp 87-97

78. Rey P, Bernier J, Goldhirsch A. Trattamento chirurgico del carcinoma della mammella: conservazione del seno. Tribuna Medica Ticinese 55: 189-94, 1990

39

79. Castiglione M, Gelber RD, Goldhirsch A, Rudenstam C.-M, Senn H.-J, Lindtner J, Brunner K, Cavalli F, Collins J, Hacking A. Adjuvant systemic therapy in elderly patients with node positive breast cancer. In: Adjuvant Therapy of Cancer VI. SE. Salmon Ed. Grune & Stratton, Orlando, 1990, pp 310-18

80. Goldhirsch A, Neuenschwander H, Castiglione M, Senn HJ, Cavalli F. Adjuvante systemische Therapie beim Mammakarzinom in den neunziger Jahren: Stand der Dinge und offene Fragen. Schweiz med Wschr 120: 1771-83, 1990

81. Castiglione-Gertsch M, Weber W, Gelber RD, Goldhirsch A, for the International Breast Cancer Study Group. Family history and prognosis of patients with node-positive breast cancer treated with adjuvant therapy. In: Hereditary Cancer and Preventive Surgery, W. Weber, U. Laffer, M. Dürig (eds), Karger Verlag, Basel, 1990, pp. 105-114

82. Castiglione M, Goldhirsch A. Is the adjuvant therapy for node-negative disease necessary? Diagn. Oncol. 1: 98-101, 1991

83. Goldhirsch A, Gelber R.D, Castiglione M, for the International Breast Cancer Study Group. Adjuvant therapy of breast cancer. Eur. J Cancer 27: 389-99, 1991

84. Gelber R.D., Goldhirsch A. Meta-analysis: The fashion of summing-up evidence. Part I. Rationale and conduct. Ann Oncol 2: 461-68, 1991

85. Castiglione M, Goldhirsch A. Die adjuvante systemische Therapie beim Mammakarzinom heute. Acta Chir Austriaca 23: 49-56, 1991

86. Goldhirsch A, Gelber RD. Trials of adjuvant chemotherapy for operable breast cancer. In: High-Risk Breast Cancer. J. Ragaz, A. Ariel Eds, Springer Verlag, Heidelberg 1991, pp 237-49

87. Gelber RD, Goldhirsch A. Comment on «the use of subjective rankings in clinical trials with an application to cardiovascular disease». Stat in Med 11: 439-441, 1992

88. Gelber RD, Goldhirsch A. Methods for weighing benefits and toxicities. In: Adjuvant Therapy of Breast Cancer. I. Craig Henderson Ed. Kluwer Academic Publishers, Boston, 1992, pp 189-206

89. Pagani-Santoro O, Goldhirsch A. Biologia del carcinoma mammario: possibili applicazioni cliniche. Progressi in Oncol Clin 3 (Suppl 1): 11-40, 1992

90. Gelber RD, Coates AS, Goldhirsch A. Meta-analysis: the fashion of summing up evidence. Part II: Interpretation and uses. Ann Oncol 3: 683-91, 1992

91. Goldhirsch A. Trattamento precauzionale del carcinoma mammario: Consensus 1992. Tribuna Med Ticinese 57: 767-70, 1992

92. Gelber RD, Castiglione M, Hürny C, Bernhard J, Coates A, Goldhirsch A. Reporting results from adjuvant therapy trials with special emphasis on quality-of-life findings. In: Endocrine Therapy for Breast Cancer V. A. Goldhirsch Ed. ESO, European School of Oncology Monographs, U. Veronesi Series Ed. Springer Verlag, Berlin, 1992, pp 73-88

93. Goldhirsch A, Castiglione M, Gelber RD. Adjuvant chemoendocrine therapies in pre - and postmenopausal breast cancer. In: Endocrine Therapy for Breast Cancer V. A. Goldhirsch Ed. ESO, European School of Oncology Monographs, U. Veronesi Series Ed. Springer Verlag, Berlin, 1992, pp 89-103

94. Gelber RD, Goldhirsch A. From the overview to the patient: How to interprete meta-analysis data. In: Adjuvant Therapy of Primary Breast cancer. Recent Results in Cancer Research, HJ. Senn, A Goldhirsch, RD Gelber, B Thürlimann Eds, Springer Verlag, Berlin, 1993, pp 221-34

40

95. Gelber RD, Cole BF, Goldhirsch A. How to quality of life of breast cancer patients in clinical trials. In: Adjuvant Therapy of Primary Breast cancer. Recent Results in Cancer Research, HJ. Senn, A Goldhirsch, RD Gelber, B Thürlimann Eds, Springer Verlag, Berlin, 1993, pp 167-76

96. Gelber RD, Goldhirsch A, Coates AS. Adjuvant therapy for breast cancer: understanding the Overview. J Clin Oncol 11: 580-85, 1993

97. Gelber RD, Goldhirsch A, Cole BF. Evaluation of effectiveness: Q-TWiST. Cancer Treatm Rev 19 (Suppl. A): 73-84, 1993

98. Senn H-J, Castiglione M, Goldhirsch A, Gelber RD. Survey of International Breast Cancer Study Group (IBCSG) Trials- and an optimistic look for innovative studies in the future. In Adjuvant Therapy of Cancer VII. S.E. Salmon, Ed. J.B. Lippincott Company, Philadelphia, 1993, pp 162-74

99. Castiglione M, Schnürch HG, Bender HG, Goldhirsch A. Prinzipien der adjuvanten medikamentösen Therapie beim Mammakarzinom. Gynäkologe 27: 49-63, 1994

100. Marini G, Alerci M, Pesce G, Goldhirsch A. Approccio algoritmico al trattamento dell’epatocarcinoma. Tribuna Med Ticinese 60: 145-150, 1995

101. Veronesi U, Goldhirsch A, Yarnold J. Breast Cancer. In Oxford Textbook of Oncology, M. Peckham, HM. Pinedo and U. Veronesi Eds. Oxford Medical Publications, Oxford, New York, Tokyo, 1995, pp 1243-89

102. Goldhirsch A, Castiglione-Gertsch M. Adjuvante Systemtherapie des Mammakarzinoms. Arch Gynecol Obstet 256 (Suppl): S 93-103, 1995

103. Gelber RD, Cole BF, Gelber S, Goldhirsch A. The Q-TWiST method. in Quality of life and Pharmacoeconomics in Clinical Trials. Second Edition. B. Spilker Ed. Lippincott-Raven Publishers, Philadelphia, 1996, pp 437-44

104. Castiglione-Gertsch M, Gelber RD, Goldhirsch A. Adjuvant systemic therapy: the issue of timing and sequence. In Adjuvant Therapy of Breast Cancer V. H-J. Senn, RD. Gelber, A. Goldhirsch, B. Thürlimann Eds., Recent Results in Cancer Research. Springer Verlag, Berlin, 1996, vol 40, pp 201-13

105. Goldhirsch A. Radiation therapy as part of primary treatment. Summary. In Adjuvant Therapy of Breast Cancer V. HJ. Senn, RD. Gelber, A. Goldhirsch, B. Thürlimann Eds. Recent Results in Cancer Research. Springer Verlag, Berlin, 1996, vol 40, pp 273-75

106. Marini G, Goldhirsch A, Cavalli F. Ruolo della chemioterapia ad alto dosaggio con autotrapianto di cellule staminali nel trattamento del carcinoma mammario: realtà, controversie e scelte terapeutiche. Tribuna Med Ticinese 61: 349-52, 1996

107. Pagani O, Rey P, Goldhirsch A. Sostituzione ormonale per la menopausa: prevenzione senza rischi? Tribuna Med Ticinese 61: 353-57, 1996

108. Goldhirsch A, Gelber RD. Endocrine therapies of breast cancer. Semin Oncol 23: 494-505, 1996

109. Goldhirsch A. Breast cancer. In Textbook of Medical Oncology, F. Cavalli, HH. Hansen, SB. Kaye Eds. Martin Dunitz, London, UK 1997, pp 53-86

110. Peto R, Collins R, Sackett D, Darbyshire J, Babiker A, Buyse M Stewart H, Baum M, Goldhirsch A, Bonadonna G, Valagussa P, Rutqvist L, Elbourne D, Davies C, Dalesio O, Palmar M, Hill C, Clarke M, Gray R, Doll R. The trials of Dr. Bernard Fisher: a European perspective on an American episode. Control Clin Trials 18: 1-13, 1997

41

111. Colleoni M, Audisio RA, deBraud F, Fazio N, Martinelli G, Goldhirsch A. Practical considerations in the treatment of hepatocellular carcinoma. Drugs 55: 367-382, 1998

112. Colleoni M, Coates A, Pagani O, Goldhirsch A. Combined chemo-endocrine adjuvant therapy for patients with operable breast cancer: still a question? Cancer Treat Rev 24: 15-26, 1998

113. Goldhirsch A, Colleoni M, Coates AS, Castiglione-Gertsch M, Gelber RD for the International Breast Cancer Study Group. Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: Are all CMFs alike? Ann Oncol 9: 489-93, 1998

114. Goldhirsch A, Coates AS, Castiglione-Gertsch M, Gelber RD. New treatments for breast cancer: Breakthroughs for patient care or just steps in the right direction? Ann Oncol 9: 973-76, 1998

115. Orecchia R, Colleoni M, Petit JY, Goldhirsch A. Neoplasie della Mammella: Strategia terapeutica integrata. In Oncologia Chirurgica, Umberto Veronesi Editor. Masson, Milano, Parigi, Barcellona 1999, pp 269-82

116. Gelber RD, Bonetti M, Cole BF, Gelber S, Goldhirsch A. Quality of life assessment in the adjuvant setting: is it relevant? In Adjuvant Therapy of Primary Breast Cancer VI. HJ. Senn, RD. Gelber, A. Goldhirsch, B. Thürlimann Eds. Recent Results in Cancer Research. Springer Verlag, Berlin, 1998, pp 373-89

117. Orecchia R, Colleoni M, Petit JY, Goldhirsch A. Strategia terapeutica integrata. In Oncologia Chirurgica. U. Veronesi Ed. Masson, Milano, Parigi, Barcellona, 1999, pp 269-81

118. Goldhirsch A, Locatelli M, Colleoni M. Chemioterapia primaria: razionale e risultati. In: Senologia Oncologica, U.Veronesi Ed. Masson, Milano, 1999, pp. 359-61.

119. Goldhirsch A, Locatelli M, Colleoni M. Terapia delle metastasi occulte: razionale e risultati del trattamento adiuvante. In: Senologia Oncologica. U.Veronesi Ed. Masson, Milano, 1999, pp.449-58.

120. Öberg K, Goldhirsch A, Neville AM. Neoplastic disorders of the adrenal gland. In: Textbook of Uncommon Cancer. Second Edition. D. Raghavan, M.L. Brecher, D.H. Johnson, N.J. Meropol, P.L. Moots, J.T. Thigpen Eds. John Wiley & Sons, New York, 1999, pp 239-58

121. Veronesi U, Sacchini V, Colleoni M, Goldhirsch A. Breast cancer, In UICC Manual of Clinical Oncology, 7th edition. Raphael E. Pollock Ed. Wiley-Liss. Inc. 1999, pp 491-513

122. Colleoni M, Orlando L, Nolè F, Goldhirsch A; International Breast Cancer Study Group. Introducing taxanes in the adjuvant treatment of breast cancer: expectations and reality. Breast 9: 134-38, 2000

123. Veronesi U, Costa A, Zurrida S, Goldhirsch A, Colleoni M, Cinieri S, Marsiglia H, Gelber S, Castiglione-Gertsh M, Jellins J, Cataliotti L, Sacchini V, Kurtz J, Dixon JM, Orvieto E, Braun S, Siena S; European Institute of Oncology; European School of Oncology. Breast cancer at the end of a successful century: meeting highlights from the First Milan Breast Cancer Conference and discussion paper for the Second Conference (Milan, 14-16 June, 2000). Breast 9: 161-70, 2000

124. Piccart M, Goldhirsch A, Straehle C. The Breast International Group. a new spirit of collaboration in breast cancer research for the new millennium. Eur J Cancer. 36: 1733-36, 2000.

125. Veronesi U, Goldhirsch A, Costa A, Zurrida S. New technologies for diagnosis and treatment of breast cancer: meeting highlights from the Second Milan Breast Cancer Conference (Milan, 14-16 June, 2000). Breast 10: 243-56, 2001

42

126. Colleoni M, Gelber RD, Gelber S, Castiglione-Gertsch M, Coates AS, Goldhirsch A. How to improve timing and duration of adjuvant chemotherapy. Breast 10 (Suppl 3): 101-105, 2001

127. Bonetti M, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Coates AS, for the International Breast Cancer Study Group. Features that predict responsiveness to chemotherapy and endocrine therapies. Breast 10 (Suppl 3): 147-57, 2001

128. Coates AS, Hurny C, Peterson HF, Bernhard J, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, for the International Breast Cancer Study Group. Quality of life scores predict outcome in metastatic but not in early breast cancer. Breast 10 (Suppl 3): 164-70, 2001

129. Coates A, Goldhirsch A, Gelber R. Overhauling the breast cancer overview: are subsets subversive? Lancet Oncol 3: 525-26, 2002

130. Goldhirsch A, Colleoni M, Gelber RD. Endocrine therapy of breast cancer. Ann Oncol 13 (Suppl 4): 61-68, 2002

131. Gelber S, Cole BF, Goldhirsch A, Gelber RD. The Q-TwiST Method. Breast Cancer Online 5: issue 11, 2002

132. Colleoni M, Goldhirsch A. Adjuvant systemic therapies for patients with breast cancer: Endocrine responsiveness and effects of chemotherapy. Curr Probl Cancer 27: 13-16, 2003

133. Veronesi U, Goldhirsch A, Costa A, Zurrida S. New technologies for diagnosis and treatment of breast cancer: meeting highlights from the Fourth Milan Breast Cancer Conference (Milan, June 5-7, 2002). Breast 12: 223-35, 2003

134. Gelber RD, Castiglione-Gertsch M, Coates AS, Goldhirsch A. Tailored treatment investigations for premenopausal women with endocrine responsive (ER+ and/or PgR+) breast cancer: The open questions. Breast. 12 (Suppl): S43-4, 2003

135. Gelber RD, Bonetti M, Goldhirsch A. Tailoring treatments for the individual patient. Breast. 12 (Suppl): S15, 2003

136. Colleoni M, Zarieh D, Gelber RD, Viale G, Luini A, Veronesi P, Intra M, Galimberti V, Renne G, Goldhirsch A. Preoperative systemic treatment: prediction of responsiveness. Breast. 12: 538-42, 2003

137. Gelber RD, Bonetti M, Castiglione-Gertsch M, Coates AS, Goldhirsch A. Tailoring adjuvant treatments for the individual breast cancer patient. Breast 12: 558-68, 2003

138. Senn HJ, Thurlimann B, Goldhirsch A, Wood WC, Gelber RD, Coates AS. Comments on the St. Gallen consensus 2003 on the primary therapy of early breast cancer. Breast 12: 569-82, 2003

139. Goldhirsch A, Gelber RD. Breast Cancer in Young Women. In: Diseases of the Breast, 3rd edition, Harris JR, Lippman ME, Morrow M, Osborne CK. Ed. Lippincott Williams & Wilkins, 2004, pp 1339-1349

140. Goldhirsch A, Colleoni M. Breast cancer. In Textbook of Medical Oncology, F Cavalli, HH. Hansen, SB. Kaye Eds. Taylor & Francis, Abingdon, UK 2004, pp 85-117

141. Dellapasqua S, Colleoni M, Gelber RD, and Goldhirsch A. Adjuvant endocrine therapy for premenopausal women with early breast cancer. J Clin Oncol 23: 1736-1750, 2005

142. Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G. Breast cancer. Lancet 365: 1727-1741, 2005

43

143. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn H-J & Panel Members. Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. Ann Oncol 16: 1569-1583, 2005

144. Price KN and Goldhirsch A. Clinical trial update: International Breast Cancer Study Group. Commentary. Breast Cancer Res 7: 252-254, 2005

145. Curigliano G, Spitaleri G, Pietri E, Rescigno M, de Braud F, Cardillo A, Munzone E, Rocca A, Ionizzi G, Brichard V, Orlando L & Goldhirsch A. Breast cancer vaccines: a clinical reality or fairy tale? Ann Oncolo 17: 750-762, 2006

146. Veronesi U, Viale G, Rotmensz N, Goldhirsch A. Rethinking TNM: Breast cancer TNM classification for treatment decision-making and research. Breast 15: 3-8, 2006

147. Cinieri S, Colleoni M, Zurrida S, Goldhirsch A, Veronesi U. Innovation in care and research: meeting highlights from the seventh Milan Breast Cancer Conference (Milan, 15-17 June, 2005). Breast 15: 232-245, 2006

148. Pagani O & Goldhirsch A. Breast cancer in young women: climbing for progress in care and knowledge. Women’s Health 2: 717-732, 2006

149. Dellapasqua S, Colleoni M, Goldhirsch A. Focusing on physical function limitations in elderly women surviving cancer: any opportunità for improvement? Nat Clin Pract Oncol 3: 598-599, 2006

150. Goldhirsch A, Coates AS, Gelber RD, Glick JH, Thürlimann B & Senn H-J. On behalf of the St Gallen Expert Panel Members. First – select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol 17: 1772-1776, 2006

151. Crivellari D, Aapro M, Leonard R, von Minckwitz G, Brain E, Goldhirsch A, Veronesi A, and Muss H. Breast cancer in the elderly. J Clin Oncol 25: 1882-1890, 2007

152. Curigliano G, Spitaleri G, Dettori M, Locatelli M, Scarano E, Goldhirsch A. Vaccine immunotherapy in breast cancer treatment: promising, but still early. Expert Rev Anticancer Ther 7: 1225-1241, 2007

153. Curigliano G, Spitaleri G, Fingert HJ, de Braud F, Sessa C, Loh E, Cipolla C, De Pas T, Goldhirsch A, Shah R. Drug-induced QTc interval prolongation: A proposal towards an efficient and safe anticancer drug development. Eur J Cancer 44: 494-500, 2008

154. Azim HA Jr, Peccatori FA, Liptrott SJ, Catania C and Goldhirsch A. Breast cancer and pregnancy: how safe is trastuzumab? Nat Rev Clin Oncol 6: 367-370, 2009

155. Partridge AH, Goldhirsch A, Gelber S, and Gelber RD, Breast Cancer in Younger Women. In: Diseases of the Breast, 4th edition, Harris JR, Lippman ME, Morrow M, Osborne CK. Ed. Lippincott Williams & Wilkins, 2009, pp 1073-1082

156. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn H-J & Panel members. Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20: 1319-1329, 2009

157. Colleoni M, Dellapasqua S and Goldhirsch A. Breast cancer. In Textbook of Medical Oncology, 4th Edition. Cavalli F, Kaye SB, Hansen HH, Armitage JO, Piccart-Gebhart MJ eds. Informa Healthcare, London, UK 2009, pp 77-105

158. Goldhirsch A, Price KN. Adjuvant endocrine therapy in premenopausal women with operable breast cancer: understanding the issues. Oncology (Williston Park) 24: 331-332, 2010

159. Curigliano G, Mayer EL, Burstein HJ, Winer EP, Goldhirsch A. Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog Cardiovas Dis 53: 94-104, 2010

44

160. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn H-J & Panel members. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22: 1736-1747, 2011

161. Gnant M, Piccart-Gebhart M, Goldhirsch A, Baselga J, Cameron D, Di Leo A, Dowsett M, Gelber R, von Minckwitz G, Waldvogel C & Straehle C. Developing an international network for breast cancer research: the BIG experience. Clin Invest 1: 623-628, 2011

162. Munzone E, Curigliano G, Burstein HJ, Winer EP, Goldhirsch A. CMF revisited in the 21st century. Ann Oncol 23: 305-311, 2012

163. Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov J, Kyriakides S, Lin N, Pagani O, Senkus E, Thomsson C, Aapro M, Bergh J, Di Leo A, El Saghir N, Ganz PA, Gelmon K, Goldhirsch A, Harbeck N, Houssami N, Hudic C, Leadbeater M, Mayer M, Rodger A, Rugo H, Sacchini V, Sledge G, Van’t Veer L, Viale G, Krop I, Winer E. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 21: 242-252, 2012

45

Letters and Comments

1. Joss RA, Goldhirsch A, Brunner KW, Galeazzi RL. Sudden death in a cancer patient on high-dose domperidone (letter). Lancet i: 1019, 1982

2. Pedrazzini A, Cavalli F, Kiser J, Goldhirsch A. Early onset thrombocytopenia in the chemotherapy of testicular teratoma. (letter). Eur J Cancer Clin Oncol 19: 867, 1983

3. Goldhirsch A, Gelber RD. Chemoendocrine versus endocrine therapy in breast cancer (letter). Lancet ii: 922-923, 1984

4. Goldhirsch A, Gelber RD, Cavalli F, Rudenstam CM, Tattersall MNH, for the Ludwig Breast Cancer Study Group. Adjuvant therapy in postmenopausal node-positive breast cancer (letter). J Clin Oncol 3: 1045, 1985

5. Goldhirsch A, Gelber RD, Tattersall MNH, Rudenstam CM, Cavalli F, for the Ludwig Breast Cancer Study Group. Endocrine adjuvant therapy for breast cancer (letter). Lancet i: 1274, 1985

6. Goldhirsch A, Gelber RD, Tattersall MNH, Rudenstam CM, Cavalli F. Methotrexate / nitrous oxide toxic interaction in perioperative chemotherapy for early breast cancer (letter). Lancet ii: 151, 1987

7. Gelber RD, Goldhirsch A. Meta-analysis in clinical research (letter). Ann Intern Med 108: 158-59, 1988

8. Goldhirsch A. Mammakarzinom ohne Lymphknotenbefall (letter). Münch med Wschr 131: 12, 1989

9. Gelber RD, Goldhirsch A, Castiglione M, for the International Breast Cancer Study Group. The duration of a life of quality should become the focus of " quality-of-life " studies. (letter). J Clin Oncol 7: 542-43, 1989

10. Goldhirsch A, Gelber RD, Castiglione M, for the International Breast Cancer Study Group. Adjuvant therapy for node-negative breast cancer.(letter). N Engl J Med 321: 473, 1989

11. Gelber RD, Goldhirsch A. Menstrual effect on surgical cure of breast cancer (letter). Lancet ii: 1344, 1989

12. Goldhirsch A, Castiglione M, Gelber RD. Adjuvant chemo-endocrine therapy in postmenopausal women with breast cancer and axillary-node metastases. (letter). Lancet 335, 1099-100, 1990

13. Goldhirsch A, Gelman RS, Gelber RD, Castiglione M. Treatment of breast cancer in elderly patients (letter). Lancet 336: 564, 1990

14. Neville AM, Bettelheim R, Gelber RD, Goldhirsch A. Occult axillary lymph-node micrometastases in breast cancer (letter). Lancet 336: 759, 1990

15. Neville AM, Price KN, Gelber RD, Goldhirsch A. Axillary node micrometastases and breast cancer (letter). Lancet 337: 1110, 1991

16. Gelber RD, Goldhirsch A. Quality-adjusted survival analysis. (letter). J Clin Oncol 9: 526, 1991

17. Taylor CW, Anbazhagan R, Jayatilake H, Adams A, Gusterson BA, Price K, Gelber RD, Goldhirsch A. Helix pomatia in breast cancer. (letter). Lancet 338: 580, 1991

46

18. Goldhirsch A, Gelber RD, Forbes J, Price K, Castiglione M, Rudenstam C-M, Lindtner J, Hacking A, Senn HJ. Timing breast cancer surgery (letter). Lancet 338: 691-692, 1991.

19. Goldhirsch A, Gelber RD, Peterson H, Neville AM. Host factors in breast cancer recurrence (letter). J Clin Oncol 10: 1118-19, 1992

20. Gelber RD, Goldhirsch A, Castiglione M, Rudenstam C-M, Senn H-J, on behalf of the International Breast Cancer Study Group (IBCSG). Premenopausal oophorectomy versus CMF chemotherapy in stage II breast carcinoma (letter). Lancet 342: 305, 1993

21. Goldhirsch A, Gelber RD, Castiglione M, Senn H.-J. Doxorubicin adjuvant combinations for breast cancer (letter). Lancet 342: 1551, 1993

22. Goldhirsch A, Gelber RD, Castiglione M. Testing tumor dormancy in breast cancer (letter). J Natl Cancer Inst 86: 558, 1994

23. Goldhirsch A, Gelber RD. Adjuvant therapy for breast cancer (letter). N Engl J Med 331: 745, 1994

24. Goldhirsch A, Laffer UT, Metzger U, Aeberhard P, Maibach R, Castiglione M. Adjuvant intraportal chemotherapy for colorectal cancer (letter). Lancet 345: 1184, 1995

25. Gelber RD, Goldhirsch A. Sector resection with or without postoperative radiotherapy for stage I breast cancer: five-year results of a randomized trial (letter). J Natl Cancer Inst 87: 689, 1995

26. Gelber S, Gelber RD, Cole BF, Goldhirsch A. The Q-TWiST Method. Quality of Life News Letter 16: 3-4, 1996

27. Gelber RD, Goldhirsch A, Cole BF, Krook JE. Re: A Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer (letter). J Natl Cancer Inst 88: 1686, 1996

28. Spataro V, Goldhirsch A. Breast cancer: relevance of estrogen receptor determination at relapse (letter). J. Clin Oncol 15: 862, 1997

29. Martinelli G, Peccatori F, Ullrich B, Ghielmini M, Ruggero E, Goldhirsch A. Clinical manifestation of severe hyperammonaemia in patients with multiple myeloma (letter). Ann Oncol 8: 751-756, 1997

30. Goldhirsch A, Coates AS, Colleoni M, Gelber RD. Radiotherapy and chemotherapy in high-risk breast cancer (letter). N Engl J Med 338: 330, 1998

31. Colleoni M, Orlando L, Robertson C, Nole F, Peruzzotti G, Cassano R, Orvieto E, Viale G, Goldhirsch A. Assessment of response in primary chemotherapy for breast cancer (letter). Ann Oncol 9: 1140-41, 1998

32. Coates AS, Gelber RD, Goldhirsch A. Subsets within the chemotherapy overview (letter). Lancet 352: 1783-84, 1998

33. Cole BF, Gelber RD, Goldhirsch A. Response to: Interferon toxicity worse in retrospect; Impact on Q-TWiST? & Can the Q-TWiST method provide information on patients’ preferences without collecting preference data from patients? (letter) J Clin Oncol 16: 3718, 1998

34. De Pas T, Martinelli G, De Braud F, Peccatori F, Catania C, Aapro MS, Goldhirsch A. Friedreich's ataxia and intrathecal chemotherapy in a patient with lymphoblastic lymphoma (letter). Ann Oncol 10: 1393, 1999

35. Locatelli M, Colleoni M, Noberasco C, Nole F, Orlando L, Munzone E, Peruzzotti G, Goldhirsch A. Hepatic toxicity from cyclophosphamide, methotrexate, fluorouracil. (letter) Ann Oncol 10: 1394-95, 1999

47

36. Orlando L, Colleoni M, Nolè F, Biffi R, Rocca A, Curigliano G, Ferretti G, Peruzzotti G, de Braud F, Masci G, Goldhirsch A.Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): Is prophylaxis required? (letter) Ann Oncol 11: 117-18, 2000

37. Munzone E, Nole F, Orlando L, Mandala M, Biffi R, Ciano C, Villa G, Civelli M, Goldhirsch A. Unexpected right phrenic nerve injury during 5-fluorouracil continuous infusion plus cisplatin and vinorelbine in breast cancer patients (letter). J Natl Cancer Inst. 92: 755, 2000.

38. Castiglione-Gertsch M, Gelber RD, O'Neill A, Coates AS, Goldhirsch A. Systemic adjuvant treatment for premenopausal node-negative breast cancer. The International Breast Cancer Study Group (letter). Eur J Cancer. 36: 549-50, 2000.

39. Goldhirsch A, Francis P, Castiglione-Gertsch M, Gelber RD, Coates AS. Taxanes as adjuvant for breast cancer (letter). Lancet 356: 507, 2000

40. Curigliano G, Ferretti G, Colleoni M, Marrocco E, Peruzzotti G, De Cicco C, Paganelli G, Goldhirsch A. Bone scan had no role in the staging of 765 consecutive operable T(1-2)N(0-1) breast cancer patients without skeletal symptoms (letter). Ann Oncol 12: 724-25, 2001

41. Gelber S, Gelber RD, Coates AS, Goldhrisch A, Castiglione-Gertsch M. Too early to say that pregnancy has an antitumor effect on breast cancer (letter). J Clin Oncol 19: 3707-708, 2001

42. Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A. Policheotherapy for early breast cancer (letter). Lancet 358: 2170, 2001

43. Bertolini F, Martinelli G, Goldhirsch A. Mosaic tumour blood vessels and high-dose chemotherapy for breast cancer (letter). Lancet Oncol 2: 595, 2001

44. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: international consensus panel on the treatment of primary breast cancer (letter). J Clin Oncol 20: 879-880, 2002

45. Curigliano G, Mandala M, Minchella I, Goldhirsch A. Mediastinal lymphoadenopathy in a patient with breast cancer (letter). Lancet Oncol 3: 174, 2002

46. Colleoni M, Goldhirsch A, Coates AS, Gelber RD, Gelber S, and Castiglione-Gertsch M. Perioperative chemotherapy in patients with node-negative postmenopausal breast cancer. (letter). J Clin Oncol 20: 2210 – 12, 2002

47. Di Cosimo S, Ferretti G, Fazio N, Mandala M, Curigliano G, Bosari S, Intra M, Latronico A, Goldhirsch A. Breast and ovarian metastatic localization of signet-ring cell gastric carcinoma. (letter) Ann Oncol; 14: 803-804, 2003

48. Bonomo M, Mingrone W, Brauchli P, Hering F, Goldhirsch A. Exemestane seems to stimulate tumour growth in men with prostate carcinoma (letter). Eur J Cancer 9: 2111-12, 2003

49. Colleoni M, Rotmensz N, Martinelli G, Gelber RD, Coates A, Goldhirsch A. Lesson learned from high-dose chemotherapy for high-risk breast cancer (What you see is what you mean) (letter). Ann Oncol 15: 355-56, 2004

50. Crivellari D, Goldhirsch A, Coates A. Hormonal Treatment Duration in Elderly Patients: An Open Question (letter). J Clin Oncol 22: 1164-65, 2004

51. Peccatori F, Martinelli G, Gentilini O, and Goldhirsch A. Chemotherapy during pregnancy: what is really safe? (letter). Lancet Oncol 5: 398, 2004

52. Saletti P, Ghielmini M, Martinoli S, Goldhirsch A. Sustained complete remission of metastatic oesophageal adenocarcinoma using long-term therapy with 5-fluorouracil (letter). Ann Oncol 15: 1145-46, 2004

48

53. Fazio N, De Pas T, de Braud F, Spaggiari L, Mazzarol G, Biffi R, Andreoni B, Zampino M, Curigliano G, Lorizzo K, Di Meglio G & Goldhirsch A. CDX-2 should be included in the work-up of patients with lung metastases from unknown primary (letter). Ann Oncol 15: 1850, 2004

54. De Pas T, Colleoni M, Orlando L, Masci G, Rocca A, Catania C, Curigliano G, Manzoni S, Goldhirsch A & de Braud F. Reply to the arcitcle «Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity» by V. R. Rozados et al. (Ann Oncol 2004; 15: 1543-1550: … and in humans? (letter) Ann Oncol, 16: 673, 2005

55. Sanna G, Zampino MG, Pelosi G, Nolè F & Goldhirsch A. Jaw avascular bone necrosis associated with long-term use of biphosphonates. (letter) Ann Oncol 16: 1207-1213, 2005

56. Goldhirsch A, Gelber RD, Viale G, Colleoni M, Coates AS. Prediction of cancer outcome with microarrays. (letter) Lancet 365:1685-1686; author reply 1686, 2005

57. Gianni L, Colleoni M, Golding JF & Goldhirsch A. Can tamoxifen relieve motion sickness? (letter) Ann Oncol, 16: 1713-1714, 2005

58. Colleoni M, Li S, Gelber RD, Price KN, Coates AS, Castiglione-Gertsch M, and Goldhirsch A, for the International Breast Cancer Study Group. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. (research letter) Lancet: 366: 1108-1110, 2005

59. Curigliano G, Colleoni M, Mandala M, De Pas T, Spitaleri G, de Braud F, Goldhirsch A. Prophylaxis for venous thromboembolism in cancer patients with a central vein catheter: new tones for an old song. (letter) J Clin Oncol. 23:7243-4, 2005

60. Curigliano G, Formica V, De Pas T, Spitaleri G, Pietri E, Fazio N, de Braud F & Goldhirsch A. Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy. (letter) Ann Oncol 17: 1174-1175, 2006

61. Colleoni M, Gelber S & Goldhirsch A. Reply to the letter to the editor on “Cost-opportunity analysis in clinical oncology; from the «wild far-west» to a correct integration of the disciplines, avoiding the «war of the worlds», by D. Tassinary et al. (Ann Oncol 2006; 17: 877). (letter) Ann Oncol 17: 878, 2006

62. Curigliano G, Magni E, Renne G, De Corbelli O, Rescigno M, Torrisi R, Spitaleri G, Pietri E, de Braud F, Goldhirsch A. «Burned out» phenomenon of the testis in retroperitoneal seminoma. (letter) Acta Oncol 45: 335-336, 2006

63. Curigliano G, Spitaleri G, de Braud F & Goldhirsch A. Reply to Letter to the Editor: ‘Toxic epidermal necrolysis in patients with malignancies’, by Gravante G, Esposito G, Marianetti M, Delogu D, Sconocchia G & Montone A (doi:10.1093/annonc/mdl089). (letter) Ann Oncol 17: 1601-1602, 2006

64. Cardillo A, De Cicco C, Paganelli G, Ghisini R, Peruzzotti G, Balduzzi A, Goldhirsch A, Rotmensz N, Veronesi P, Luini A, Intra M, Colleoni M. Role of fluorodeoxyglucose positron emission tomography in the staging of patients with breast cancer candidated to surgery. (letter) Ann Oncol 18: 394-395, 2007

65. Conti-Beltraminelli M, Pagani O, Ballerini G, Richetti A, Graffeo R, Ruggeri M, Forni V, Pianca S, Schönholzer C, Mainetti C, Cavalli F & Goldhirsch A. Henoch-Schönlein purpura (HSP) during treatment with anastrozole. (letter) Ann Oncol 18: 205-207, 2007

66. Goldhirsch A, Price KN. Comparing aromatase inhibitors in the absence of clinical trial results can be misleading. (letter) J Surg Oncol 95: 355-356, 2007

67. Fazio N, Biffi R, Curigliano G, Lorizzo K, Zampino MG, de Braud F, Chiappa A, Roth A, Goldhirsch A. Re: Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. (letter) J Natl Cancer Inst 99: 1345-1346, 2007

49

68. Cathomas R, Goldhirsch A, von Moos R. Drug-induced immune thrombocytopenia. (letter) N Engl J Med 357: 1870-1871, 2007

69. Curigliano G, Balduzzi A, Goldhirsch A, Colleoni M. Daily low-dose aspirin in cancer patients with central venous catheter: new role for an old drug. (letter) Support Care Cancer 16: 313-314, 2008

70. Azim HA Jr, Peccatori FA, Scarfone G, Acaia B, Rossi P, Cascio R, Goldhirsch A. Anthracyclines for gestational breast cancer: course and outcome of pregnancy. (letter) Ann Oncol 19: 1511-1512, 2008

71. Sanna G, Preda L, Bruschini R, Cossu Rocca M, Verri E, Bellomi M, Goldhirsch A, Nole F. The role of surgery in jaw bone necrosis associated with long-term use of bisphosphonates. (letter) Acta Oncol 47: 476-478, 2008

72. Crivellari D, Colleoni M, Dellapasqua S, and Goldhirsch A. Metronomic chemotherapy in elderly patients: do risks exceed benefits in some patients? (letter) Tumori 95: 130-131, 2009

73. Veronesi U, Zurrida S, Goldhirsch A, Rotmensz N, Viale G. Breast Cancer Classification: Time for a change. (comments and controversies) J Clin Oncol 27: 2427-2428, 2009

74. Coates AS, Goldhirsch A, Gelber RD, Ingle JN, Thürlimann B, Senn HJ. Reply to Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer? (letter) Ann Oncol 20: 1751-1752, 2009

75. Curigliano G, Bagnardi V, Fumagalli L, Rotmensz N, Locatelli M, Viale G, Goldhirsch A. Reply to D Crivellari. (letter) J Clin Oncol 28: e258-e259, 2010

76. Purushotham A, Pinder S, Cariati M, Harries M, Goldhirsch A. Neoadjuvant chemotherapy: not the best option in estrogen receptor-positive, HER2-negative, invasive classical lobular carcinoma of the breast? J Clin Oncol 28: 3552-3554, 2010

77. Zurrida S, Montagna E, Naninato P, Colleoni M, Goldhirsch A. Receptor status (ER, PgR and HER2) discordance between primary tumor and locoregional recurrence in breast cancer. (letter) Ann Oncol 22:479-480, 2011

78. Farante G, Zurrida S, Galimberti V, Veronesi P, Curigliano G, Luini A, Goldhirsch A, Veronesi U. Erratum to: The management of ductal intraepithelial neoplasia (DIN): open controversies and guidelines of the Istituto Europeo di Oncologia (IEO), Milan, Italy. Breast Cancer Res Treat 128: 379, 2011

79. Giovannetti E, Pistilli B, Bellettini G, Codacci-Pisanelli G, Losekoot N, Curigliano G, Peccatori F, Goldhirsch A, Azim Jr HA, & Peters GJ. «The only thing I know is that I know nothing»: 5-fluorouracil in human milk. (letter) Ann Oncol 23: 543-544, 2012

80. Coates AS, Colleoni M, Goldhirsch A. Is adjuvant chemotherapy useful for women with luminal A breast cancer? J Clin Oncol 30: 1260-1263, 2012

81. Iorfida M, Dellapasqua S, Bagnardi V, Cardillo A, Rotmensz N, Mastropasqua MG, Bottiglieri L, Goldhirsch A, Viale G, Colleoni M. HER2-negative (1+) breast cancer with unfavorable prognostic features: to FISH or not to FISH? Ann Oncol 23: 1371-1372, 2012

50

Books (Editor and Co-editor)

1. A. Goldhirsch. Adjuvant Therapy in Early Breast Cancer: a Critical Review. Docent dissertation, presented to the Faculty of Medicine, University of Bern, December, 1983

2. U. Eppenberger, A. Goldhirsch. Endocrine Therapy and Growth Regulation of Breast Cancer. Recent Results in Cancer Research. Springer Verlag, Berlin, 1988

3. H-J. Senn, A. Goldhirsch, R.D. Gelber, B. Osterwalder. Adjuvant Therapy of Primary Breast Cancer. Recent results in Cancer research. Springer Verlag, Berlin, 1989

4. A. Goldhirsch. Endocrine Therapy of Breast Cancer IV. Concepts & Strategies. European School of Oncology Monographs, Springer Verlag, 1990.

5. U.Veronesi (Ed), S. Ciatto, P. Boyle, A. Goldhirsch, E. Van der Schueren, U. Pastorino. Breast Cancer. Textbook for general Practitioners. Edited by Springer-Verlag for Europe Against Cancer, European Commission Series for General Practitioners, 1990

6. A. Goldhirsch. Endocrine Therapy of Breast Cancer V. European School of Oncology Monographs, Springer Verlag, 1992.

7. H-J. Senn, R.D. Gelber, A. Goldhirsch, B. Thürlimann. Adjuvant Therapy of Breast Cancer IV. Recent Results in Cancer research. Springer Verlag, Berlin, 1993

8. H-J. Senn, R.D. Gelber, A. Goldhirsch, B. Thürlimann. Adjuvant Therapy of Breast Cancer V. Recent Results in Cancer Research. Springer-Verlag, Berlin, 1996

9. V. Bartsch, Systemic Treatment of Breast Cancer. Ciba Monography, A. Goldhirsch and K. Possinger eds., Springer-Verlag Berlin, Heidelberg, New York, 1996

10. H-J. Senn, R.D. Gelber, A. Goldhirsch, B. Thürlimann. Adjuvant Therapy of Primary Breast Cancer VI. Recent Results in Cancer Research. Springer Verlag, Berlin, 1998

Documents

A Goldhirsch List of publications - Oncology · PDF fileSchweiz med Wschr 109: 1741-42, 1979 9. ... 1983 28. Goldhirsch A, ... Prognostic significance of tumor grade in clinical trials